Supporting Information:

Messages that increase COVID-19 vaccine acceptance: Evidence from online experiments in six Latin American countries

Contents

S1 Survey registration, recruitment, and screening

Recruitment

Respondents in each country were recruited via Netquest's online panels between January 11 and January 29, 2021. Netquest maintains large panels of survey respondents in most Latin American countries, including at least 125,000 panelists in all six countries in this study. Panelists are regularly invited to take surveys, although this is not their primary vocation. Netquest's dynamic enrollment protocols updated invitations to ensure that the sample frame was nationally representative in terms of sex, age category, socioeconomic status, and region. Upon clicking a link to participate, respondents reached a Qualtrics landing page, where information about the academic study was provided and consent to participate in the study was obtained. As the summary statistics in Table S1 verify, the marginal distribution of respondents that started the survey (i.e. reached our screening juncture) closely approximated the Census distribution for these variables. Unsurprisingly for an online survey, respondents are less representative in terms of education, which Netquest did not seek to balance with population averages.

Screening

In addition to screening out respondents who were already willing to take a vaccine within less than 2 months of it becoming available, we also screened out respondents aged below 18 (n=9) or who failed our attention check eleven questions into the main survey (by failing to correctly identify the capital city of their country; n=11). Given these few screen outs, our sample of hesitant respondents is also likely to be broadly nationally representative of this subgroup. The median completed survey lasted 26 minutes; respondents who completed the survey were compensated with approximately 3 US dollars. Respondents who took less than 10 minutes to complete the survey (n=47) were excluded from the experimental analyses.

	Argentina		Brazil		Chile		Colombia		Mexico		Peru	
	Survey	**Census**	**Survey**	**Census**	**Survey**	**Census**	**Survey**	**Census**	**Survey**	**Census**	**Survey**	**Census**
Age	44.34	47.33	40.69	41.34	44.54	44.18	39.82	42.54	39.17	42.44	39.7	41.99
Male	0.49	0.53	0.50	0.49	0.51	0.48	0.48	0.48	0.49	0.48	0.47	0.48
Socioeconomic status												
Low	0.17	0.13	0.28	0.26	0.33	0.42	0.49	0.43	0.33	0.33	0.49	0.42
Middle	0.77	0.8	0.64	0.66	0.58	0.48	0.40	0.45	0.45	0.46	0.45	0.50
High	0.06	0.07	0.07	0.08	0.10	0.10	0.11	0.12	0.21	0.21	0.06	0.08
Education												
None	0.00	0.13	0.06	0.11	0.01	0.00	0.01	0.05	0.00	0.14	0.01	0.05
Primary	0.13	0.43	0.11	0.49	0.07	0.23	0.02	0.38	0.03	0.16	0.01	0.20
Secondary	0.48	0.32	0.53	0.27	0.47	0.46	0.32	0.29	0.44	0.54	0.36	0.51
Higher	0.23	0.07	0.21	0.13	0.28	0.22	0.51	0.16	0.31	0.14	0.34	0.14
Other higher	0.15	0.06	0.09		0.18	0.10	0.14	0.11	0.22	0.01	0.28	0.10

Table S1: Summary statistics among pre-screened respondents by country. The survey data pertain to our pre-screened sample. The Census data is drawn from the most recent available Census data, with the exception of the data for socioeconomic level, which was provided by Netquest.

S2 Vaccine information and motivational message treatment conditions

The following script shows the full information script received by different vaccine information treatment groups, in both English and then Spanish (the Portuguese translations are available upon request):

> *[Control and all treatment groups]* Latin American countries are beginning to distribute their first doses of vaccines.
> Los países de Latinoamérica están comenzando a distribuir sus primeras dosis de vacunas.
>
> *[All treated groups]* The next screen will provide **important information about these COVID-19 vaccines**.
> Vaccines are designed to **prevent disease**.
> After **extensive testing by medical experts**, different countries have approved the use of various vaccines against COVID-19.
> Clinical tests have shown that the vaccines are **safe and highly effective** in preventing mild and severe COVID-19 infections. The **side effects are generally minor** and you cannot get COVID-19 from the vaccine.
> La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.
> Las vacunas están diseñadas para **prevenir enfermedades**.
> Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.
> Las pruebas clínicas han demonstrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.
>
> *[Biden treatment group only]* A few weeks ago, **President Joe Biden safely received a vaccine** against COVID-19 in the United States.
> Hace algunas semanas, **el presidente Joe Biden recibió, de manera segura, una vacuna** contra el COVID-19 en los Estados Unidos.
>
> *[Herd and Current treatments conditions only]* If enough people get vaccinated against COVID-19, the coronavirus will stop spreading.
> Some experts say that **at least [60/70/80]% of people need to be vaccinated to prevent the spread of the coronavirus**.
> Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagarse.
> Algunos expertos dicen que **al menos [60/70/80]% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

		Information about vaccines?									
								Vaccine + Herd + Current			
		None	*Vaccine*	*Vaccine + Biden*	*Vaccine + Herd 60%*	*70%*	*80%*	*60%*	*70%*	*80%*	Pooled
Motivational message?	*None*	3/56	3/56	1/28	1/56	1/56	1/56	1/56	1/56	1/56	1/4
	Altruism	3/56	3/56	1/28	1/56	1/56	1/56	1/56	1/56	1/56	1/4
	Economic recovery	3/56	3/56	1/28	1/56	1/56	1/56	1/56	1/56	1/56	1/4
	Social approval	3/56	3/56	1/28	1/56	1/56	1/56	1/56	1/56	1/56	1/4
	Pooled	3/14	3/14	1/7	1/14	1/14	1/14	1/14	1/14	1/14	

Table S2: Informational treatments factorial design. The numbers in each cell indicate the share of the sample randomized into each condition within each country.

> *[Current treatments conditions]* Recent data indicates that **X% of people in [COUNTRY] currently say they would get vaccinated** against COVID-19.
> Datos de esta encuesta indican que **X% de las personas en [COUNTRY] actualmente dicen que se vacunarían** contra el COVID-19.

The control group only received the basic text in black, while the Vaccine, Herd, and Current components of the information treatments were successively shown on further screens (the Current information was shown together with the Herd expert opinion). The expert opinion of the vaccination rate required to achieve herd immunity randomly varies across treatment variants reporting 60%, 70%, or 80%—the most frequently cited numbers cited by experts around the time the survey was designed. Respondents that received the Current component of the information treatment were informed of the rate of vaccine willingness in their country according to recent surveys (for the first around 200 respondents per country) or the early respondents to this survey (all subsequent respondents). The text was all shown in black, but the emboldened sections were emboldened within Qualtrics. In each treatment condition, respondents were given a quick quiz to ensure that they internalized key information on each screen.

The eight different treatment groups are described in Table S2. The probability distribution used for the randomization assignment of conditions is arrayed along the x axis.

After receiving the information treatments described in the previous section, respondents were independently randomly assigned to receive a motivational message. A control group received no message, while the altruism, economic recovery, and social approval messages are shown below in English and then Spanish (the Portuguese translations are available upon request):

> *[Altruism]* Getting vaccinated against COVID-19 helps stop the spread of COVID-19 and thus prevents the most vulnerable from getting sick.
> By getting vaccinated against COVID-19, **you will help keep others in your community healthy**.
> Vacunarse contra el COVID-19 ayuda a detener la propagación del COVID-19 y

así evita que los más vulnerables se enfermen.
Si usted se vacuna contra el COVID-19, **ayudará a mantener saludables a otros en su comunidad**.

[Economic recovery] The faster [COUNTRY] can stop the spread of COVID-19, the faster people will get back to work.
If you get vaccinated against COVID-19, **you will help the economy recover**.
Cuanto más rápido [COUNTRY] pueda detener la propagación de COVID-19, más rápido las personas volverán a trabajar.
Si usted se vacuna contra el COVID-19, **ayudará a que la economía se recupere**.

[Social approval] Getting vaccinated against COVID-19 shows that you care about others in your community.
If you get vaccinated against COVID-19, **you will be respected by the people in your community**.
Vacunarse contra el COVID-19 demuestra que usted se preocupa por los demás en su comunidad.
Si usted se vacuna contra el COVID-19, **será respetado por las personas en su comunidad**.

As shown in Table S2, these motivational treatments were cross-randomized with respect to the vaccine information with equal probability.

S3 Experimental design and estimation strategies

Treatments and randomization

The full text for each treatment condition is provided in S2 Appendix. Both the information and motivational treatments were assigned within 144 blocks defined by country (6 possible values), pre-treatment vaccine willingness (6 possible values), and age category (4 possible values). Within each block, sequential complete randomization was used to assign treatments within Qualtrics. Table S3 reports the realized distribution of treatment assignments. The corresponding treatment assignment probabilities are reported in S2 Appendix.

		Information about vaccines?									
								Vaccine + Herd			
				Vaccine +	*Vaccine + Herd*			*+ Current*			
		None	*Vaccine*	*Biden*	*60%*	*70%*	*80%*	*60%*	*70%*	*80%*	Pooled
Motivational message?	*None*	378	406	274	143	127	124	128	121	143	1,844
	Altruism	401	365	254	121	127	111	128	130	119	1,756
	Economic recovery	386	351	245	124	128	139	128	133	124	1,758
	Social approval	375	390	249	120	129	126	124	133	121	1,767
	Pooled	1,540	1,512	1,022	508	511	500	508	517	507	7,125

Table S3: Distribution of treatments assignments. The numbers in each cell indicate the number of respondents randomized into each condition (pooling across countries).

Measurement of outcome variables

The full question and set of answers for each outcome variable is described in S5 Appendix.

Weighting of data

To maximize the representativeness of the descriptive data in Fig 2 in the main article, we apply population weights based on the most recent census. In particular, we weight respondents to match the population distribution at the education (none, primary, secondary, university, other higher) $\times$ sex (male, female) $\times$ region (multiple regions that differ by country) $\times$ age category (multiple categories that differ by country) cell level within each country. To maximize statistical power, we estimate treatment effects without applying population weights; however, we report qualitatively similar, if slightly larger and less precise, effects when such weights are applied in S17 Appendix. We also demonstrate robustness to using rake weights that achieve national representativeness over the marginal distribution of each covariate in S17 Appendix.

Estimating average treatment effects of vaccine information

We estimate the effect of each of the eight vaccine information treatments separately using the following pre-specified OLS regression:

$$\begin{aligned} Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau_1 Vaccine_{ic} + \tau_2 Vaccine\ and\ Biden_{ic} \\ + \sum_{k=60,70,80} \tau_3^k Vaccine\ and\ Herd\ k\%_{ic} \\ + \sum_{k=60,70,80} \tau_4^k Vaccine\ and\ Herd\ k\%\ and\ Current_{ic} + \varepsilon_{ic}, \end{aligned} \tag{1}$$

where Y_{ic} is an outcome for respondent i in country c, α_{bc} are block $\times$ country fixed effects, Y_{ic}^{pre} is a standardized version of the pre-treatment number of months that respondent i would wait to get vaccinated once eligible, $Vaccine_{ic}$ is an indicator for the basic vaccine information provided about COVID-19 vaccines, $Vaccine\ and\ Biden_{ic}$ is an indicator for additionally being informed that Biden was vaccinated, $Vaccine\ and\ Herd\ k\%$ is an indicator for receiving the basic vaccine information and being informed that experts believe that at least $k \in \{60, 70, 80\}$ percent of individuals will need to get vaccinated to prevent the spread of COVID-19, and $Vaccine\ and\ Herd\ k\%\ and\ Current_{ic}$ indicates respondents are further informed of their country's current rate of vaccine willingness. Between the fixed effects and the lagged outcome, we adjust for baseline pre-treatment hesitancy responses and increase statistical power. All observations are weighted by the inverse probability of treatment assignment and heteroskedasticity-robust standard errors are used in all regression analyses. Each τ coefficient estimates an average treatment effect of the corresponding treatment.

When pooling across information treatments, we estimate the following pre-specified OLS regression:

$$Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau Any\ vaccine\ information_{ic} + \varepsilon_{ic}, \tag{2}$$

where $Any\ vaccine\ information_{ic}$ indicates that respondent i received any information treatment and τ is the associated average treatment effect. All regression specifications were prespecified in equivalent form or noted in the text of our pre-analysis plan, which is publicly available at the Social Science Registry (www.socialscienceregistry.org/trials/7080), unless noted otherwise.

Estimating treatment effects of belief updating about herd immunity and current aggregate willingness to vaccinate

To estimate the effect of beliefs about the level of vaccination required to achieve herd immunity, conditional on having receiving basic vaccine information, we leverage experimental variation in whether a respondent was informed that experts believe 60%, 70%, or 80% of the

population is required to achieve herd immunity. The direction of updating is not random, because this depends on a respondent's prior belief. However, conditional on a given prior belief, the direction of induced belief updating randomly varies with the expert opinion regarding the vaccination rate required to achieve herd immunity. We exploit such variation by estimating the following OLS regression among the subset of respondents that received a treatment containing information about herd immunity levels:

$$Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau \mathbb{1}[Herd\ prior_{ic} < k_{ic}] + \sum_{p} \eta_p \mathbb{1}[Herd\ prior_{ic} = p] + \varepsilon_{ic}, \tag{3}$$

where the treatment $\mathbb{1}[Herd\ prior_{ic} < k_{ic}]$ is an indicator for respondent i's prior belief $Herd\ prior_{ic}$ (the percentage $p \in [0, 100]$ of the population that needs to get vaccinated to stop the propagation of COVID-19, which was elicited pre-treatment) being below the reported expert opinion on the herd immunity rate k_{ic}, and τ is the associated average treatment effect. As robustness checks, we examine more fine-grained updating treatments in S10 Appendix. This approach to estimating the effect of the herd immunity level reported was not prespecified, but complements our prespecified approach comparing the effects of the conditions providing expert opinions of 60%, 70%, and 80% herd immunity requirements.

To estimate heterogeneous effects of being informed of the current level of national willingness to vaccinate with respect to a respondent's prior belief, conditional on having receiving basic vaccine information, we estimate the following OLS regression:

$$\begin{aligned} Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau_1 Current_{ic} + \tau_2 (Current_{ic} \times \mathbb{1}[Willing\ prior_{ic} < r_{ic}]) \\ + \eta \mathbb{1}[Willing\ prior_{ic} < r_{ic}] + \varepsilon_{ic}, \end{aligned} \tag{4}$$

where $Current_{ic}$ is an indicator for i receiving information about the current rate of vaccine willingness (where the comparison group contains control respondents and respondents that received other treatment conditions that did not report current willingness), and $\mathbb{1}[Willing\ prior_{ic} < r_{ic}]$ is an indicator for a respondent's prior belief about the willingness rate in their community being below the national willingness rate $r_{ic} \in \{56, 57, 58, 61, 64, 66, 67, 73, 75, 79\}$ reported (or that would have been reported if treated). τ_1 then estimates the effect of being informed about the current level of national vaccine willingness among respondents encouraged to update upwards about the current national rate of vaccine willingness, while $\tau_1 + \tau_2$ captures the effect of treatment among respondents encouraged to update downwards about the current national rate of vaccine willingness.

We further estimate the effect of providing information relating expert opinions on herd immunity requirements to current rates of vaccine willingness, conditional on having receiving basic vaccine information. Following our approach to estimating the effect of exposure to different expert opinions about herd immunity, whether the expert herd immunity rate opinion that a respondent received is above or below the current rate of vaccine willingness was randomly assigned, conditional on the country's current rate of willingness. Interacting this variation in potential belief updating with whether a respondent received information about the current

rate then captures the effect of learning that the current rate is above or below the expert herd immunity rate, beyond exposure to a given expert herd immunity opinion. We estimate this effect using the following OLS regression among the subset of respondents that received a herd immunity treatment:

$$Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau_1 Current_{ic} + \tau_2 \mathbb{1}[r_{ic} < k_{ic}] + \tau_3 (Current_{ic} \times \mathbb{1}[r_{ic} < k_{ic}]) + \sum_p \eta_p \mathbb{1}[r_{ic} = p] + \sum_p \xi_p (Current_{ic} \times (\mathbb{1}[r_{ic} = p] - \mu_p)) + \varepsilon_{ic}, \quad (5)$$

where $\mathbb{1}[r_{ic} < k_{ic}]$ is an indicator for respondents for whom the expert opinion for the level of vaccination required to achieve herd immunity exceeded the current level of vaccine willingness, r_{ic}, in the respondent's country, and thus τ_1 and $\tau_1 + \tau_3$ estimate the effect of being informed that the current rate is above and below, respectively, what experts believe is required to attain herd immunity. The interactions between the (demeaned) fixed effects for the current rate at the time of the survey, $(\mathbb{1}[r_{ic} = p] - \mu_p)$ for each level of current willingness, and $Current_{ic}$ are included to identify the effect of $Current_{ic} \times \mathbb{1}[r_{ic} < k_{ic}]$; the fixed effects in the estimation sample are demeaned to ensure that τ_1 captures the conditional average treatment effect when $r_{ic} < k_{ic}$. This subtle strategy for estimating the effect of how the current willingness rate relates to the expert opinion was only recognized by the research team after conducting the experiment, and was thus not prespecified.

Estimating treatment effects of motivation messages

We estimate the effect of the three motivation messages by comparing each message to the control group receiving no message using the following pre-specified OLS regression:

$$Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau_1 Altruism_{ic} + \tau_2 Economic\ recovery_{ic} + \tau_3 Social\ approval_{ic} + \varepsilon_{ic}, \quad (6)$$

where $Altruism_{ic}$, $Economic\ recovery_{ic}$, and $Social\ approval_{ic}$ indicate whether respondent i received the respective treatment. Observations are unweighted due to the equal probabilities of treatment assignment. Each τ coefficient estimates an average treatment effect of the corresponding treatment.

Estimating heterogeneous treatment effects

To examine heterogeneity in the effect of the basic vaccine information treatment, we estimate OLS regressions of the following form:

$$Y_{ic} = \alpha_{bc} + \beta Y_{ic}^{pre} + \tau_0 Any\ vaccine\ information_{ic} + \boldsymbol{\tau}_1 (Any\ vaccine\ information_{ic} \times \mathbf{X}_{ic}) + \boldsymbol{\gamma} \mathbf{X}_{ic} + \varepsilon_{ic}, \quad (7)$$

where $\mathbf{X}_{ic}$ is a vector of predetermined respondent-level characteristics. To estimate heterogeneity in the effect of the motivational treatments, we estimate analogous equations where we replace $Any\ vaccine\ information_{ic}$ with indicators for the three motivational messages.

Statistical inference

All statistical inferences are derived from two-tailed t tests and 95% confidence intervals based on the regressions previously described. The two-tailed tests are more conservative than the one-tailed tests for positive average treatment effects than we pre-specified.

Computing persuasion rates

Following standard practice in the information and persuasion literature [1], we compute the persuasion rate as: $100 \times \frac{ATE}{1-Y_0}$, where ATE is a given average treatment effect of interest and Y_0 is the (post-treatment) control group mean outcome. The persuasion rate captures the share of the non-willing that become willing due to treatment. Since all treated respondents were directly exposed to treatment, we do not adjust for the share of respondents that engaged with treatment.

Support for the identifying assumptions

The average treatment effects are identified under two assumptions: (i) the stable unit treatment value assumption (SUTVA); and (ii) unconfounded treatment assignment. SUTVA almost certainly holds because interference between respondents between start and end of the survey is implausible in the large countries under study and because versions of treatment were controlled by the research team. Although treatments were randomly assigned, identification of causal effects could be confounded by chance imbalances or differential attrition across treatment groups. As S7 Appendix shows, neither potential concern drives the results and the results are robust to bounding our estimates to address differences in attrition [2]. The identification conditions for conditional average treatment effects are analogous within subgroups.

Implementation of statistical analyses

All statistical analyses were implemented in R, with the exception of initial data cleaning and implementation of the bounding exercises that were conducted in Stata.

S4 Manipulation checks

To test whether the vaccine information was internalized by treated respondents, we asked two questions later in the survey about the basic vaccine information received by all treated respondents. This information was not included in the comprehension quiz that appeared with each component of the treatment information. In particular, respondents were asked whether vaccines had yet been approved in some countries and whether there were only minimal side effects of the vaccines. The results in Table S4 show that respondents receiving any vaccine information were almost 0.05 probability points more likely to answer the first question correctly, relative to an already high share of respondents in the control group that answered correctly (0.78), and 0.11 probability points more likely to answer the second more difficult question correctly. Although there was some heterogeneity by specific information treatment (even though all treated respondents received the information relating to the questions), all conditions significantly increased vaccine knowledge. The smaller effects associated with the treatments including information about the current level of willingness in a respondent's country suggests a possibility for information overload.

	Outcome variables:	
	Know that vaccines were approved	Know that there are minimal side effects
Panel A: Pooled across vaccine information treatments		
Any vaccine information	0.044***	0.110***
	(0.011)	(0.014)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.78	0.45
Control outcome std. dev.	0.42	0.50
Observations	7,033	7,019
R^2	0.078	0.095
Panel B: By vaccine information treatment condition		
Vaccine	0.035**	0.091***
	(0.015)	(0.018)
Vaccine + Biden	0.034**	0.084***
	(0.016)	(0.020)
Vaccine + Herd 60%	0.085***	0.137***
	(0.019)	(0.025)
Vaccine + Herd 70%	0.078***	0.143***
	(0.019)	(0.025)
Vaccine + Herd 80%	0.084***	0.153***
	(0.019)	(0.025)
Vaccine + Herd 60% + Current	0.016	0.151***
	(0.021)	(0.025)
Vaccine + Herd 70% + Current	0.030	0.094***
	(0.020)	(0.025)
Vaccine + Herd 80% + Current	0.033	0.095***
	(0.020)	(0.025)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.78	0.45
Control outcome std. dev.	0.42	0.50
Observations	7,033	7,019
R^2	0.074	0.103

Table S4: Vaccine information comprehension tests. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S5 Measurement of outcome variables

We focus on four primary outcome variables capturing intention to vaccinate:

1. *Vaccine willingness scale*: a five-point scale ranging from "strongly disagree" (1) to "strongly agree" (5) capturing a respondent's willingness to get vaccinated if a vaccine were available. The specific question was: "To what extent do you agree or disagree? If a vaccine against COVID-19 were available, I would get vaccinated. Strongly disagree? Disagree? Neither agree nor disagree? Agree? Strongly agree? Not sure?" In Spanish, this read as: "¿Hasta qué punto está usted de acuerdo o en desacuerdo? Si una vacuna contra el COVID-19 estuviera disponible, yo me vacunaría. Muy en desacuerdo? En desacuerdo? Ni de acuerdo ni en disacuerdo? De acuerdo? Muy de acuerdo? No estoy seguro?"

2. *Willing to take a vaccine*: an indicator coded one for respondents that answered "agree" or "strongly agree" to the previous question.

3. *Months would wait to get vaccinated*: number of months, top-coded at 12, that a respondent would wait to get vaccinated if a COVID-19 vaccine were available to you now. The specific question was: "If a vaccine against COVID-19 were available to you now, how many months would you wait before get vaccinated? Number of month: ...? I would not take a vaccine?" In Spanish, this read as: "Si una vacuna contra el COVID-19 estuviera disponible para usted ahora, ¿cuántos meses esperaría antes de vacunarse? Numero de meses: ...? Nunca tomaría una vacuna?"

4. *Encourage others to get vaccinated*: an indicate coded 1 for respondents that responded "somewhat likely" or "very likely" to the following question: "How likely are you to encourage family or friends to get vaccinated? Never? Unlikely? Somewhat likely? Very likely?" In Spanish, this read as: "¿Qué tan probable es que motive a familiares o amigos a que se vacunen? Nada probable? Poco probable? Algo probable? Muy probable?"

(Portuguese translations are available upon request.) These questions appeared a few screens after the motivation treatments were delivered. Identical versions of the first three variables were elicited at the beginning of the survey to determine whether a respondent would be screened based on already being willing to take a vaccine (see S1 Appendix for more information about screening). While the first three outcomes were pre-specified as primary outcomes, we included the encourage others outcome in light of the positive effect and the high salience of social dynamics in our findings.

Since we could not measure actual vaccination because vaccine rollouts in Latin America were limited at the time of the study, we tried to measure vaccine willingness behaviorally by assessing whether respondents choose to receive additional information about COVID-19 vaccines from the Pan American Health Organization (PAHO) and ultimately clicked through to their website. To measure the latter, we wrote code to verify whether the link on the Qualtrics

page was clicked. These variables provide behavioral measures of interest in obtaining further information about COVID-19 vaccines. However, this may only imperfectly correlate with vaccine willingness intentions because further information may not be required to convince individuals after treatment. (At the time of the study, government websites did not have online sign-up portals that would have represented a more direct behavioral measure of interest in taking a vaccine.) Accordingly, we do not focus on this outcome in our main analysis; since it was pre-specified, we report the results for whether a respondent requested to receive the link and actually clicked through below in S16 Appendix.

S6 The main results in regression table form

Tables S5-S8 report the regression estimates that underlie Figs 4 - 7.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Any vaccine information	0.143***	0.046***	0.410***	0.037***
	(0.024)	(0.010)	(0.058)	(0.012)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.17	0.40	5.78	0.54
Control outcome std. dev.	1.18	0.49	4.38	0.50
Observations	6,951	6,951	6,876	6,659
R^2	0.483	0.492	0.766	0.356
Panel B: Argentina				
Any vaccine information	0.172***	0.043*	0.449***	0.050*
	(0.062)	(0.025)	(0.131)	(0.029)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.02	0.36	5.11	0.47
Control outcome std. dev.	1.18	0.48	4.45	0.50
Observations	1,160	1,160	1,150	1,109
R^2	0.442	0.462	0.801	0.351
Panel C: Brazil				
Any vaccine information	0.200***	0.081***	0.344**	0.027
	(0.052)	(0.022)	(0.148)	(0.028)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.30	0.42	5.92	0.49
Control outcome std. dev.	1.18	0.49	4.42	0.50
Observations	1,213	1,213	1,187	1,134
R^2	0.603	0.576	0.730	0.400
Panel D: Chile				
Any vaccine information	0.177***	0.070***	0.392***	0.068**
	(0.060)	(0.024)	(0.128)	(0.030)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	2.89	0.31	4.80	0.46
Control outcome std. dev.	1.23	0.46	4.39	0.50
Observations	1,114	1,114	1,106	1,080
R^2	0.511	0.501	0.810	0.351
Panel E: Colombia				
Any vaccine information	0.187***	0.074***	0.326***	0.067**
	(0.059)	(0.024)	(0.119)	(0.028)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.18	0.39	6.08	0.57
Control outcome std. dev.	1.16	0.49	4.18	0.50
Observations	1,131	1,131	1,120	1,085
R^2	0.460	0.484	0.819	0.378
Panel F: México				
Any vaccine information	0.054	0.002	0.507***	0.009
	(0.065)	(0.026)	(0.155)	(0.028)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.49	0.54	6.77	0.69
Control outcome std. dev.	1.21	0.50	4.26	0.46
Observations	1,102	1,102	1,098	1,075
R^2	0.415	0.477	0.717	0.311
Panel G: Perú				
Any vaccine information	0.061	0.004	0.417**	0.004
	(0.055)	(0.026)	(0.169)	(0.029)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.14	0.39	5.99	0.57
Control outcome std. dev.	1.04	0.49	4.31	0.49
Observations	1,231	1,231	1,215	1,176
R^2	0.404	0.411	0.702	0.296

Table S5: Effect of any vaccine information on vaccine willingness. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Vaccine	0.148***	0.045***	0.346***	0.047***
	(0.032)	(0.013)	(0.083)	(0.016)
Vaccine + Biden	0.121***	0.039***	0.377***	0.018
	(0.037)	(0.015)	(0.095)	(0.018)
Vaccine + Herd 60%	0.092**	0.036*	0.410***	0.029
	(0.046)	(0.019)	(0.121)	(0.022)
Vaccine + Herd 70%	0.187***	0.051***	0.531***	0.042*
	(0.047)	(0.020)	(0.120)	(0.022)
Vaccine + Herd 80%	0.131***	0.043**	0.347***	0.011
	(0.045)	(0.019)	(0.126)	(0.022)
Vaccine + Herd 60% + Current	0.183***	0.081***	0.520***	0.079***
	(0.046)	(0.020)	(0.126)	(0.022)
Vaccine + Herd 70% + Current	0.183***	0.067***	0.408***	0.064***
	(0.046)	(0.020)	(0.119)	(0.022)
Vaccine + Herd 80% + Current	0.102**	0.010	0.510***	0.010
	(0.049)	(0.020)	(0.131)	(0.022)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.17	0.40	5.78	0.54
Control outcome std. dev.	1.18	0.49	4.38	0.50
Observations	6,951	6,951	6,876	6,659
R^2	0.433	0.442	0.716	0.339

Table S6: Effect of different types of vaccine information on vaccine willingness. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Current	0.140^{**}	0.079^{***}	0.105	0.076^{***}
	(0.064)	(0.027)	(0.166)	(0.029)
Current rate below herd opinion	0.088	0.027	0.047	0.024
	(0.057)	(0.023)	(0.146)	(0.027)
Current × Current rate below herd opinion	-0.185^{**}	-0.104^{***}	-0.115	-0.084^{**}
	(0.083)	(0.034)	(0.214)	(0.037)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.30	0.45	6.04	0.53
Control outcome std. dev.	1.20	0.50	4.49	0.50
Observations	2,955	2,955	2,919	2,821
R^2	0.441	0.444	0.712	0.364

Table S7: The effect of being informed that the current rate of vaccination willingness in the population is above/below the rate required for herd immunity. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Altruism	0.022	0.014	0.074	0.018
	(0.030)	(0.013)	(0.080)	(0.014)
Economic recovery	0.051*	0.021*	−0.011	0.030**
	(0.030)	(0.013)	(0.080)	(0.014)
Social approval	0.105***	0.046***	0.252***	0.042***
	(0.030)	(0.013)	(0.084)	(0.014)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.24	0.42	6.07	0.55
Control outcome std. dev.	1.17	0.49	4.41	0.50
Observations	6,951	6,951	6,876	6,659
R^2	0.442	0.456	0.728	0.337
Panel B: Argentina				
Altruism	0.004	−0.016	0.251	0.017
	(0.073)	(0.031)	(0.185)	(0.036)
Economic recovery	0.115*	0.034	0.004	0.005
	(0.069)	(0.031)	(0.180)	(0.035)
Social approval	0.076	0.038	0.244	0.013
	(0.076)	(0.033)	(0.178)	(0.037)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.14	0.40	5.76	0.52
Control outcome std. dev.	1.11	0.49	4.40	0.50
Observations	1,160	1,160	1,150	1,109
R^2	0.417	0.441	0.773	0.330
Panel C: Brazil				
Altruism	−0.052	−0.004	0.112	−0.017
	(0.063)	(0.027)	(0.214)	(0.033)
Economic recovery	0.024	0.019	0.435**	0.035
	(0.063)	(0.028)	(0.196)	(0.033)
Social approval	0.110*	0.051*	0.633***	0.028
	(0.060)	(0.027)	(0.208)	(0.034)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.41	0.46	5.97	0.49
Control outcome std. dev.	1.19	0.50	4.45	0.50
Observations	1,213	1,213	1,187	1,134
R^2	0.580	0.546	0.683	0.387
Panel D: Chile				
Altruism	0.164**	0.086***	0.061	0.042
	(0.080)	(0.030)	(0.172)	(0.036)
Economic recovery	0.145*	0.072**	0.153	0.069*
	(0.079)	(0.030)	(0.191)	(0.035)
Social approval	0.263***	0.126***	0.408**	0.076**
	(0.079)	(0.030)	(0.197)	(0.036)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	2.92	0.31	5.17	0.49
Control outcome std. dev.	1.22	0.46	4.53	0.50
Observations	1,114	1,114	1,106	1,080
R^2	0.463	0.472	0.760	0.330
Panel E: Colombia				
Altruism	0.035	0.032	0.666***	0.077**
	(0.078)	(0.032)	(0.167)	(0.034)
Economic recovery	0.017	0.012	0.138	0.042
	(0.076)	(0.032)	(0.172)	(0.034)
Social approval	0.117	0.045	0.256	0.087**
	(0.075)	(0.031)	(0.179)	(0.035)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.26	0.41	5.96	0.57
Control outcome std. dev.	1.16	0.49	4.47	0.50
Observations	1,131	1,131	1,120	1,085
R^2	0.424	0.449	0.784	0.343
Panel F: México				
Altruism	−0.007	−0.001	−0.121	0.045
	(0.082)	(0.033)	(0.212)	(0.035)
Economic recovery	−0.004	−0.002	−0.245	0.045
	(0.090)	(0.034)	(0.225)	(0.035)
Social approval	0.035	0.006	−0.015	0.047
	(0.083)	(0.033)	(0.226)	(0.036)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.54	0.55	7.23	0.66
Control outcome std. dev.	1.16	0.50	4.02	0.48
Observations	1,102	1,102	1,098	1,075
R^2	0.349	0.422	0.673	0.293
Panel G: Perú				
Altruism	−0.001	−0.006	−0.486**	−0.050
	(0.071)	(0.033)	(0.214)	(0.035)
Economic recovery	0.023	−0.004	−0.494**	−0.012
	(0.069)	(0.032)	(0.199)	(0.036)
Social approval	0.043	0.014	0.006	0.009
	(0.072)	(0.033)	(0.227)	(0.035)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.16	0.39	6.35	0.58
Control outcome std. dev.	1.08	0.49	4.34	0.49
Observations	1,231	1,231	1,215	1,176
R^2	0.360	0.369	0.679	0.291

Table S8: Effect of different types of motivational message on vaccine willingness. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S7 Identification checks

As noted in S3 Appendix, our estimation of treatment effects relies on two assumptions: SUTVA and unconfounded treatment assignment. While SUTVA almost certainly holds in our context of online surveys where around 1,000 individuals were randomly assigned treatments in each country, there remains a risk that the random assignment of treatments could be broken by differences in attrition—that is to say in the likelihood of continuing the survey to answer post-treatment outcomes across—across experimental groups. We examine differences in attrition between treatment groups and the control group by using our main regression specifications to examine whether treatments differentially affected the probability of answering post-treatment outcome questions.

Table S9 reports the results for receiving any vaccine information. Panel A pools across countries and indicates that respondents that received any vaccine information were around 2 percentage points less likely to answer our main outcome questions. Panels B-G indicate that this difference is driven primarily by respondents in Colombia and Perú. Within the pooled sample, the difference in answering our three main outcome questions between treated and control respondents is statistically significant in each case, although the difference is relatively small in magnitude. Among the treated respondents, we find no evidence of differential attrition between treatment arms: for each of our three main outcomes, we fail to reject the null hypothesis that the response rate is identical across the eight different treatment groups ($p = 0.47$, $p = 0.40$, and $p = 0.64$, respectively).

We next turn to attrition for the motivational message treatments reported in Table S10. Focusing again on the estimates that pool across countries in panel A, we observe more substantial differences in attrition between the message and control groups: for each message, the probability of answering the post-treatment questions is around 5 percentage points higher. Again, we fail to reject the null hypothesis that there is no difference in attrition between each type of message treatment ($p = 0.42$).

These differences raise the concern that the estimates could be biased if certain types of respondent are more likely to attrite when they receive certain treatment conditions. To gauge whether such differential attrition is likely to bias our estimates, we first examine balance across pre-treatment covariates before and after respondents had the opportunity to attrite. Column (1) of Tables S11 and S12 examines balance at the point of assignment—before attrition could kick in. Consistent with the integrity of the randomized assignment of treatment, differences between treatment and control groups are consistent with chance: of 81 pre-treatment covariates, we reject at the 10% level the null hypothesis that the mean in each experimental (treatment or control) group is equal in only 4 cases for the vaccine information treatments and in 14 cases for the motivation treatments. Columns (2)-(4) next examine how differences in pre-treatment covariates change once attrition by the time that different outcome variables are reached is accounted for. If differences in attrition across experimental groups break the randomization because attrition did not occur at random within groups, we should expect differences to emerge at this point. However, the results indicate that significant imbalances do not arise due to attrition:

	Outcome variable:		
	Answered vaccine willingness scale (1)	Answered wait until vaccination (2)	Answered encourage others to get vaccinated (3)
Panel A: All countries pooled			
Any vaccine information	-0.017^{***}	-0.017^{***}	-0.023^{***}
	(0.003)	(0.004)	(0.006)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.99	0.98	0.95
Control outcome std. dev.	0.10	0.15	0.21
Observations	7,125	7,125	7,125
R^2	0.032	0.040	0.046
Panel B: Argentina			
Any vaccine information	-0.002	-0.003	-0.017
	(0.010)	(0.012)	(0.016)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.98	0.97	0.95
Control outcome std. dev.	0.14	0.16	0.22
Observations	1,184	1,184	1,184
R^2	0.025	0.021	0.029
Panel C: Brazil			
Any vaccine information	-0.023^{***}	-0.012	-0.011
	(0.008)	(0.014)	(0.019)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.99	0.96	0.92
Control outcome std. dev.	0.10	0.20	0.28
Observations	1,248	1,248	1,248
R^2	0.033	0.042	0.040
Panel D: Chile			
Any vaccine information	-0.019^{**}	-0.013	-0.015
	(0.010)	(0.012)	(0.016)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.98	0.97	0.95
Control outcome std. dev.	0.13	0.17	0.22
Observations	1,149	1,149	1,149
R^2	0.031	0.048	0.036
Panel E: Colombia			
Any vaccine information	-0.019^{***}	-0.026^{***}	-0.033^{**}
	(0.007)	(0.009)	(0.014)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	1.00	0.99	0.97
Control outcome std. dev.	0.06	0.09	0.18
Observations	1,154	1,154	1,154
R^2	0.030	0.029	0.041
Panel F: México			
Any vaccine information	-0.008	-0.013^{**}	-0.017
	(0.006)	(0.007)	(0.011)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.99	0.99	0.98
Control outcome std. dev.	0.09	0.09	0.16
Observations	1,119	1,119	1,119
R^2	0.053	0.047	0.055
Panel G: Perú			
Any vaccine information	-0.030^{***}	-0.032^{***}	-0.044^{***}
	(0.008)	(0.011)	(0.014)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.99	0.98	0.96
Control outcome std. dev.	0.09	0.13	0.20
Observations	1,271	1,271	1,271
R^2	0.030	0.039	0.059

Table S9: Effect of receiving any vaccination information on responding to main post-treatment outcome questions. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:		
	Answered vaccine willingness scale (1)	Answered wait until vaccination (2)	Answered encourage others to get vaccinated (3)
Panel A: All countries pooled			
Altruism	0.050***	0.052***	0.052***
	(0.006)	(0.007)	(0.009)
Economic recovery	0.045***	0.046***	0.047***
	(0.006)	(0.007)	(0.009)
Social approval	0.049***	0.052***	0.052***
	(0.006)	(0.007)	(0.009)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.94	0.93	0.90
Control outcome std. dev.	0.24	0.26	0.30
Observations	7,125	7,125	7,125
R^2	0.046	0.043	0.039
Panel B: Argentina			
Altruism	0.041***	0.043**	0.044**
	(0.015)	(0.017)	(0.022)
Economic recovery	0.044***	0.053***	0.041*
	(0.014)	(0.016)	(0.023)
Social approval	0.052***	0.058***	0.066***
	(0.014)	(0.016)	(0.021)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.95	0.93	0.90
Control outcome std. dev.	0.22	0.25	0.30
Observations	1,184	1,184	1,184
R^2	0.043	0.037	0.039
Panel C: Brazil			
Altruism	0.048***	0.039**	0.023
	(0.015)	(0.018)	(0.024)
Economic recovery	0.036**	0.017	0.022
	(0.016)	(0.020)	(0.024)
Social approval	0.048***	0.044**	0.032
	(0.015)	(0.018)	(0.023)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.94	0.93	0.89
Control outcome std. dev.	0.24	0.26	0.32
Observations	1,248	1,248	1,248
R^2	0.038	0.034	0.024
Panel D: Chile			
Altruism	0.056***	0.062***	0.057***
	(0.016)	(0.017)	(0.020)
Economic recovery	0.058***	0.053***	0.044**
	(0.016)	(0.018)	(0.021)
Social approval	0.044**	0.054***	0.048**
	(0.017)	(0.018)	(0.021)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.93	0.92	0.90
Control outcome std. dev.	0.26	0.27	0.30
Observations	1,149	1,149	1,149
R^2	0.046	0.050	0.031
Panel E: Colombia			
Altruism	0.048***	0.067***	0.069***
	(0.013)	(0.016)	(0.021)
Economic recovery	0.038***	0.056***	0.057***
	(0.014)	(0.017)	(0.022)
Social approval	0.044***	0.055***	0.060***
	(0.014)	(0.017)	(0.022)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.95	0.93	0.89
Control outcome std. dev.	0.23	0.26	0.31
Observations	1,154	1,154	1,154
R^2	0.050	0.050	0.035
Panel F: México			
Altruism	0.040***	0.043***	0.057***
	(0.013)	(0.013)	(0.017)
Economic recovery	0.038***	0.034**	0.050***
	(0.013)	(0.015)	(0.018)
Social approval	0.041***	0.040***	0.038**
	(0.013)	(0.014)	(0.019)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.95	0.95	0.92
Control outcome std. dev.	0.21	0.22	0.27
Observations	1,119	1,119	1,119
R^2	0.058	0.050	0.062
Panel G: Perú			
Altruism	0.063***	0.056***	0.064***
	(0.016)	(0.019)	(0.022)
Economic recovery	0.055***	0.061***	0.068***
	(0.016)	(0.018)	(0.022)
Social approval	0.061***	0.061***	0.069***
	(0.017)	(0.019)	(0.023)
Outcome range	{0,1}	{0,1}	{0,1}
Control outcome mean	0.92	0.91	0.88
Control outcome std. dev.	0.26	0.28	0.33
Observations	1,271	1,271	1,271
R^2	0.048	0.037	0.046

Table S10: Effect of motivational messages on responding to main post-treatment outcome questions. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

we again observe only 4 instances where we can reject the null hypothesis of equality across experimental groups in the case of the vaccine information treatments; while there is some variation across outcome variables for the motivational messages, the overall number of imbalances is again similar in the datasets with and without attrition. In sum, this evidence suggests that the individuals that differentially attrited in certain experimental groups are not systematically different from those that did not.

Nevertheless, it remains possible that the respondents that attrited upon receiving a specific treatment condition could differ in terms of unobserved characteristics that might influence potential outcomes. To address this concerns, our second approach uses the non-parametric bounding approach proposed Lee [1] to examine how our estimates change in the case of severe forms of selection into responding to post-treatment questions. When attrition is greater in the treatment group than the comparison group, the upper (lower) bound on the treatment effect is obtained by trimming the most extreme values from the lower (upper) tail of the outcome distribution in the treatment group until the groups are of equal size (adjusting for probability of treatment assignment); the reverse holds when attrition is greater in the comparison group. This procedure, which does not rely on statistical assumptions, allows the researcher to compute a 95% confidence interval for the treatment effect that captures both uncertainty due to random assignment as well as uncertainty due to the potential selection bias induced by attrition. To implement this bounding approach, we focus on unadjusted comparisons between treatment and control groups (with inverse probability of treatment assignment weights), which exclude the fixed effects used to increase the precision of our estimates because analytic standard errors could not be obtained. Due to our randomization, the exclusion of such fixed effects does not induce bias.

Tables S13 and S14 report the 95% confidence intervals for the bounds on the effects of any vaccine treatment and the different motivational treatments in the sample that pools across countries. We do not report results for differences between information treatments (i.e. the results corresponding to Tables S6 and S7) because there is no evidence of differential between information treatments (see above). Given the limited levels of differential attrition, the confidence interval for receiving any vaccine information unsurprisingly show that the Lee bounds are relatively tight: for each estimate, the 95% confidence interval is only slightly larger than for our main estimates, and the lower bound remains statistically significantly different from zero in each case. Consequently, differences in attrition cannot account for the positive effects of basic vaccine information on vaccine willingness.

Turning to the motivational messages in Table S14, the 95% confidence intervals for the treatment effects of each message are larger due to the greater differences in attrition between the control and message groups. Panels A-C examine each motivational message separately relative to the control group, given that Lee bounds cannot be computed for multiple treatments simultaneously. The results for the social approval message show that the lower bound includes effects that are statistically indistinguishable from zero, although the upper bound equally includes effects that are much larger than our main estimates suggest. While differential attrition increases uncertainty about the exact effect of the social approval message, there are two impor-

Pre-treatment covariate	Sample for which balance is tested: Received treatment (1)	Answered vaccine willingness scale (2)	Answered wait until vaccination (3)	Answered encourage others to get vaccinated (4)
Education - None	0.603	0.529	0.649	0.662
Education - Primary	0.683	0.783	0.754	0.77
Education - Secondary	0.366	0.387	0.515	0.543
Education - Other Higher	0.378	0.33	0.416	0.397
Education - University	0.124	0.21	0.239	0.272
Gender	0.386	0.42	0.358	0.437
Running Water in Home	0.72	0.837	0.923	0.839
Sewage in Home	0.544	0.507	0.505	0.631
Electricity in Home	0.202	0.261	0.359	0.214
No Running Water, Sewage, or Electricity in Home	0.824	0.741	0.772	0.345
COVID News Consumption - TV	0.462	0.357	0.409	0.35
COVID News Consumption - Radio	0.736	0.683	0.733	0.532
COVID News Consumption - Print	0.529	0.493	0.556	0.691
COVID News Consumption - Word of Mouth	0.942	0.912	0.905	0.885
COVID News Consumption - WhatsApp	0.525	0.761	0.771	0.762
COVID News Consumption - Social Media	0.812	0.829	0.806	0.846
COVID News Consumption - News Websites	0.627	0.494	0.437	0.284
COVID Severity in Country	0.468	0.533	0.599	0.601
Herd Immunity Prior	0.237	0.289	0.275	0.291
General Vaccine Hesitancy - Protect from Disease	0.704	0.808	0.83	0.814
General Vaccine Hesitancy - Good for Community	0.994	0.998	0.996	0.996
General Vaccine Hesitancy - Trust in Government	0.143	0.247	0.313	0.339
General Vaccine Hesitancy - Follow Doctor Instructions	0.725	0.713	0.665	0.593
General Vaccine Hesitancy - Trust in International Medical Experts	0.793	0.738	0.744	0.6
General Vaccine Hesitancy - Refused Vaccine	0.567	0.529	0.542	0.622
COVID Hesitancy Reasons - Side Effects	0.421	0.276	0.275	0.207
COVID Hesitancy Reasons - Vaccine Gives COVID	0.223	0.224	0.311	0.344
COVID Hesitancy Reasons - Produced Too Quickly	0.366	0.256	0.213	0.23
COVID Hesitancy Reasons - Not Effective	0.334	0.261	0.201	0.182
COVID Hesitancy Reasons - Not At Risk of Getting COVID	0.362	0.429	0.343	0.268
COVID Hesitancy Reasons - Against Vaccines Generally	0.786	0.833	0.848	0.9
COVID Hesitancy Reasons - Prefer 'Natural' Immunity	0.197	0.243	0.305	0.232
COVID Hesitancy Reasons - Already Had COVID	0.568	0.558	0.633	0.597
COVID Hesitancy Reasons - Don't Trust Government	0.106	0.137	0.118	0.199
COVID Hesitancy Reasons - Financial Concerns	0.484	0.528	0.587	0.658
COVID Hesitancy Reasons - Other	0.594	0.602	0.642	0.517
Comorbidities - None	0.47	0.453	0.413	0.443
Comorbidities - Diabetes	0.265	0.233	0.318	0.298
Comorbidities - Cardiovascular Diseases	0.47	0.374	0.385	0.449
Comorbidities - Obesity	0.691	0.717	0.584	0.72
Comorbidities - Autoimmune Diseases	0.795	0.779	0.8	0.803
Comorbidities - Chronic Obstructive Pulmonary Disease	0.128	0.186	0.197	0.22
Comorbidities - Prefer Not To Share	0.48	0.582	0.513	0.705
Had COVID	0.952	0.987	0.976	0.979
Know Someone Seriously Ill or Passed Away COVID	0.325	0.342	0.414	0.567
COVID Economic Situation	0.337	0.425	0.446	0.228
Government Vaccine Priority	0.791	0.793	0.834	0.824
Left/Right Political Scale	0.262	0.188	0.145	0.102
Satisfied with President COVID Management	0.305	0.334	0.466	0.546
Satisfied with Mayor COVID Management	0.017**	0.022**	0.014**	0.011**
Satisfied with Health Ministry COVID Management	0.432	0.515	0.569	0.664
Would Vote for Current President	0.416	0.325	0.331	0.297
Would Vote for Current Mayor	0.772	0.697	0.581	0.538
Trust in Current President	0.332	0.459	0.534	0.539
Trust in Current Mayor	0.048**	0.097*	0.083*	0.081*
Trust in National Health Ministry	0.492	0.603	0.63	0.763
Trust in National Medical Association	0.95	0.931	0.902	0.94
Trust in Left-Wing Newspaper	0.661	0.697	0.69	0.75
Trust in Right-Wing Newspaper	0.66	0.814	0.793	0.827
Trust in Religious Leader	0.718	0.763	0.738	0.696
Trust in Local Healthcare	0.578	0.459	0.503	0.649
Trust in Armed Forces	0.423	0.439	0.476	0.578
Trust in Civil Society Organizations	0.77	0.8	0.739	0.72
Trust in Government of China	0.331	0.433	0.478	0.502
Trust in Government of U.S. Under Trump	0.031**	0.024**	0.03**	0.032**
Trust in Government of U.S. Under Biden	0.26	0.261	0.316	0.327
Trust in Government of U.K.	0.418	0.394	0.405	0.59
Trust in Government of Russia	0.242	0.26	0.232	0.231
Meeting Indoor With Non-Family Contributes to COVID	0.165	0.221	0.257	0.297
Risk Aversion 1	0.373	0.458	0.419	0.37
Risk Aversion 2	0.09*	0.159	0.179	0.116
Risk Aversion 3	0.459	0.631	0.662	0.625
Risk Aversion 4	0.479	0.6	0.52	0.345
Risk Aversion 5	0.873	0.894	0.897	0.855
Discount Rate 1	0.925	0.941	0.958	0.975
Discount Rate 2	0.842	0.892	0.848	0.848
Discount Rate 3	0.737	0.79	0.799	0.878
Discount Rate 4	0.411	0.497	0.524	0.588
Donation Amount	0.241	0.296	0.3	0.36
Important to Receive Respect and Recognition	0.756	0.784	0.716	0.764
Social Influence	0.103	0.064*	0.063*	0.091*

Table S11: Balance of vaccine information treatments over pre-treatment covariates. Each number is the p value associated with the test of the null hypothesis that no treatment condition differs from the control group in terms of a given pre-treatment covariate. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

Pre-treatment covariate	Sample for which balance is tested: Received treatment (1)	Answered vaccine willingness scale (2)	Answered wait until vaccination (3)	Answered encourage others to get vaccinated (4)
Education - None	0.799	0.458	0.455	0.467
Education - Primary	0.159	0.174	0.201	0.17
Education - Secondary	0.636	0.664	0.695	0.873
Education - Other Higher	0.828	0.856	0.823	0.961
Education - University	0.306	0.32	0.35	0.369
Gender	0.521	0.437	0.492	0.375
Running Water in Home	0.182	0.201	0.209	0.249
Sewage in Home	0.825	0.851	0.816	0.757
Electricity in Home	0.986	0.981	0.983	0.942
No Running Water, Sewage, or Electricity in Home	0.205	0.173	0.222	0.253
COVID News Consumption - TV	0.734	0.741	0.829	0.892
COVID News Consumption - Radio	0.484	0.486	0.487	0.52
COVID News Consumption - Print	0.946	0.908	0.893	0.89
COVID News Consumption - Word of Mouth	0.474	0.413	0.382	0.5
COVID News Consumption - WhatsApp	0.937	0.938	0.91	0.693
COVID News Consumption - Social Media	0.834	0.807	0.819	0.86
COVID News Consumption - News Websites	0.728	0.692	0.705	0.609
COVID Severity in Country	0.241	0.19	0.216	0.205
Herd Immunity Prior	0.211	0.308	0.387	0.275
General Vaccine Hesitancy - Protect from Disease	0.601	0.657	0.657	0.612
General Vaccine Hesitancy - Good for Community	0.209	0.301	0.263	0.272
General Vaccine Hesitancy - Trust in Government	0.385	0.462	0.399	0.516
General Vaccine Hesitancy - Follow Doctor Instructions	0.59	0.605	0.605	0.64
General Vaccine Hesitancy - Trust in International Medical Experts	0.67	0.638	0.594	0.581
General Vaccine Hesitancy - Refused Vaccine	0.988	0.965	0.978	0.932
COVID Hesitancy Reasons - Side Effects	0.99	0.98	0.98	0.955
COVID Hesitancy Reasons - Vaccine Gives COVID	0.003***	0.002***	0.003***	0.006***
COVID Hesitancy Reasons - Produced Too Quickly	0.153	0.117	0.09*	0.119
COVID Hesitancy Reasons - Not Effective	0.154	0.181	0.21	0.33
COVID Hesitancy Reasons - Not At Risk of Getting COVID	0.575	0.643	0.601	0.586
COVID Hesitancy Reasons - Against Vaccines Generally	0.867	0.858	0.935	0.842
COVID Hesitancy Reasons - Prefer 'Natural' Immunity	0.895	0.875	0.9	0.868
COVID Hesitancy Reasons - Already Had COVID	0.767	0.846	0.839	0.835
COVID Hesitancy Reasons - Don't Trust Government	0.248	0.556	0.549	0.568
COVID Hesitancy Reasons - Financial Concerns	0.245	0.322	0.324	0.349
COVID Hesitancy Reasons - Other	0.525	0.563	0.514	0.35
Comorbidities - None	0.033**	0.027**	0.029**	0.035**
Comorbidities - Diabetes	0.633	0.546	0.609	0.618
Comorbidities - Cardiovascular Diseases	0.879	0.717	0.647	0.506
Comorbidities - Obesity	0.239	0.264	0.231	0.324
Comorbidities - Autoimmune Diseases	0.898	0.852	0.859	0.93
Comorbidities - Chronic Obstructive Pulmonary Disease	0.572	0.536	0.537	0.761
Comorbidities - Prefer Not To Share	0.036**	0.059*	0.054*	0.03**
Had COVID	0.567	0.575	0.645	0.682
Know Someone Seriously Ill or Passed Away COVID	0.132	0.119	0.119	0.159
COVID Economic Situation	0.109	0.171	0.204	0.241
Government Vaccine Priority	0.112	0.082*	0.088*	0.087*
Left/Right Political Scale	0.798	0.818	0.793	0.791
Satisfied with President COVID Management	0.291	0.259	0.269	0.338
Satisfied with Mayor COVID Management	0.236	0.231	0.243	0.239
Satisfied with Health Ministry COVID Management	0.875	0.841	0.829	0.836
Would Vote for Current President	0.011**	0.013**	0.009***	0.014**
Would Vote for Current Mayor	0.542	0.573	0.696	0.603
Trust in Current President	0.681	0.706	0.701	0.737
Trust in Current Mayor	0.621	0.709	0.737	0.669
Trust in National Health Ministry	0.885	0.849	0.886	0.831
Trust in National Medical Association	0.07*	0.11	0.171	0.213
Trust in Left-Wing Newspaper	0.546	0.53	0.507	0.777
Trust in Right-Wing Newspaper	0.089*	0.106	0.099*	0.134
Trust in Religious Leader	0.832	0.818	0.8	0.751
Trust in Local Healthcare	0.028**	0.038**	0.058*	0.071*
Trust in Armed Forces	0.208	0.181	0.177	0.363
Trust in Civil Society Organizations	0.069*	0.09*	0.099*	0.141
Trust in Government of China	0.133	0.082*	0.057*	0.191
Trust in Government of U.S. Under Trump	0.579	0.578	0.555	0.742
Trust in Government of U.S. Under Biden	0.026**	0.005***	0.007***	0.018**
Trust in Government of U.K.	0.458	0.437	0.434	0.664
Trust in Government of Russia	0.642	0.884	0.879	0.791
Meeting Indoor With Non-Family Contributes to COVID	0.449	0.433	0.437	0.337
Risk Aversion 1	0.413	0.341	0.285	0.226
Risk Aversion 2	0.676	0.785	0.808	0.784
Risk Aversion 3	0.354	0.535	0.566	0.644
Risk Aversion 4	0.75	0.922	0.92	0.989
Risk Aversion 5	0.148	0.441	0.525	0.516
Discount Rate 1	0.058*	0.04**	0.049**	0.065*
Discount Rate 2	0.011**	0.013**	0.022**	0.022**
Discount Rate 3	0.006***	0.015**	0.022**	0.032**
Discount Rate 4	0.021**	0.065*	0.087*	0.106
Donation Amount	0.545	0.513	0.51	0.62
Important to Receive Respect and Recognition	0.042**	0.06*	0.083*	0.148
Social Influence	0.246	0.195	0.156	0.208

Table S12: Balance of motivational messages over pre-treatment covariates. Each number is the p value associated with the test of the null hypothesis that no treatment condition differs from the control group in terms of a given pre-treatment covariate. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Any vaccine information effect 95% confidence interval	[0.051, 0.217]	[0.017, 0.074]	[0.117, 0.686]	[0.003, 0.070]
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.24	0.42	5.98	0.56
Control outcome std. dev.	1.18	0.49	4.43	0.50
Number of selected observations	6,986	6,986	6,910	6,706
Share of control observations trimmed	0.017	0.017	0.017	0.024

Table S13: Lee bounds on the effect of any vaccine information on vaccine willingness. All 95% confidence intervals for the treatment effect are based on Lee bound estimates, where observations are weighted by the inverse probability of treatment assignment. Confidence intervals are based on robust standard errors.

tant reasons to be confident that social approval produces positive effects on vaccine willingness. First, as Table S12 shows, attrition does not induce observable differences between the social approval and control groups. This suggests that attrition plausibly occurs somewhat randomly within treatment groups, implying that it is not the most hesitant respondents that differentially attrited from the control group—the case that corresponds to the lower Lee bound. Second, because there are no differences in attrition between motivational message groups, we can estimate the effect of the the social approval treatment relative to the altruistic treatment, which seems to have had limited impact on respondents. The results in Table S15, which compares these two groups, indicates that the social approval treatment produced a significantly larger effect than the altruistic treatment. This adds further weight to the conclusion that social approval messaging could produce substantial positive effects on vaccine uptake.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: Altruism message				
Altruism effect 95% confidence interval	[-0.146, 0.209]	[-0.047, 0.064]	[-0.596, 0.598]	[-0.042, 0.079]
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.25	0.42	6.07	0.56
Control outcome std. dev.	1.18	0.49	4.43	0.50
Number of selected observations	3,471	3,471	3,431	3,321
Share of control observations trimmed	0.050	0.050	0.053	0.056
Panel B: Economic recovery message				
Economic recovery effect 95% confidence interval	[-0.107, 0.231]	[-0.037, 0.070]	[-0.606, 0.520]	[-0.027, 0.087]
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.26	0.43	6.05	0.56
Control outcome std. dev.	1.18	0.49	4.45	0.50
Number of selected observations	3,466	3,466	3,424	3,313
Share of control observations trimmed	0.047	0.047	0.048	0.051
Panel C: Social approval message				
Social approval effect 95% confidence interval	[-0.066, 0.283]	[-0.015, 0.095]	[-0.457, 0.753]	[-0.018, 0.102]
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.28	0.44	6.14	0.57
Control outcome std. dev.	1.16	0.50	4.44	0.50
Number of selected observations	3,480	3,480	3,443	3,331
Share of control observations trimmed	0.049	0.049	0.053	0.056

Table S14: Lee bounds on the effect of different types of motivational message on vaccine willingness. All 95% confidence intervals for the treatment effect are based on Lee bound estimates. Confidence intervals are based on robust standard errors.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Social approval	0.077**	0.031**	0.188**	0.024*
	(0.031)	(0.013)	(0.083)	(0.014)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.29	0.45	6.14	0.58
Control outcome std. dev.	1.17	0.50	4.45	0.49
Observations	3,485	3,485	3,452	3,346
R^2	0.446	0.466	0.724	0.348

Table S15: The effect of social approval versus altruistic motivational messages on vaccine willingness. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. The baseline category is the altruism message treatment. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S8 Differential effects of vaccine information treatments on reasons given for reducing hesitancy

Among the subset of respondents that received an information treatment, we later asked how the treatment affected their reasons for being hesitant. Since this question was only asked of treated respondents, we examine the effect of the more detailed information treatments relative to the effect of the basic vaccine information. The basic vaccine information group means at the foot of Table S16 show that respondents became less hesitant along a number of dimensions, while the treatment effect estimates indicate that no additional information treatment condition systematically affected the reasons that individuals stated for becoming less hesitant. In line with the lack of differential effect of the information treatments on our vaccine willingness outcomes, the results suggest that basic vaccine information was sufficient to significantly reduce vaccine hesitancy and that further information did not make individuals less hesitant.

	Outcome variable:								
	Less worried about side effects (1)	Less worried about getting COVID-19 from vaccine (2)	Less worried about speed of development (3)	Less worried about vaccine ineffectiveness (4)	No getting vaccinated even if low risk (5)	No longer wants immunity from infection (6)	Now getting vaccinated even if already had COVID-19 (7)	Now more trusting of government (8)	Less worried about cost (9)
Vaccine + Biden	−0.000	0.004	0.018	0.002	0.001	0.003	0.012	−0.004	−0.000
	(0.015)	(0.016)	(0.016)	(0.017)	(0.013)	(0.011)	(0.012)	(0.010)	(0.013)
Vaccine + Herd 60%	0.018	−0.022	−0.024	0.017	0.027	0.017	−0.000	0.001	−0.003
	(0.019)	(0.019)	(0.019)	(0.022)	(0.018)	(0.015)	(0.014)	(0.013)	(0.017)
Vaccine + Herd 70%	0.040**	0.022	−0.001	0.036*	−0.005	0.016	0.009	0.004	−0.020
	(0.020)	(0.020)	(0.020)	(0.022)	(0.017)	(0.015)	(0.015)	(0.013)	(0.016)
Vaccine + Herd 80%	0.023	−0.001	−0.010	0.023	0.019	0.014	0.006	0.021	0.026
	(0.019)	(0.020)	(0.019)	(0.022)	(0.017)	(0.015)	(0.015)	(0.014)	(0.018)
Vaccine + Herd 60% + Current	0.034*	−0.004	0.014	0.027	0.028	−0.012	0.003	−0.003	0.005
	(0.020)	(0.020)	(0.020)	(0.022)	(0.018)	(0.014)	(0.015)	(0.012)	(0.017)
Vaccine + Herd 70% + Current	0.035*	0.007	0.001	0.006	0.003	−0.006	−0.030**	−0.006	0.017
	(0.020)	(0.020)	(0.020)	(0.022)	(0.017)	(0.014)	(0.013)	(0.012)	(0.017)
Vaccine + Herd 80% + Current	0.005	−0.019	0.006	−0.037*	0.016	−0.003	0.004	−0.005	−0.036**
	(0.019)	(0.020)	(0.020)	(0.020)	(0.017)	(0.014)	(0.015)	(0.012)	(0.015)
Outcome range	{0,1}	{0,1}	{0,1}	{0,1}	{0,1}	{0,1}	{0,1}	{0,1}	{0,1}
Control outcome mean	0.17	0.19	0.19	0.26	0.12	0.08	0.09	0.06	0.12
Control outcome std. dev.	0.38	0.39	0.39	0.44	0.32	0.27	0.28	0.25	0.32
Observations	5,619	5,619	5,619	5,619	5,619	5,619	5,619	5,619	5,619
R^2	0.103	0.081	0.069	0.151	0.057	0.047	0.095	0.070	0.062

Table S16: Effect of different types of vaccine information on reasons for becoming less hesitant, among treated respondents. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Because control respondents did not answer this question, the baseline category is the Vaccine only information treatment. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S9 Heterogeneity in the effect of basic vaccine information

To understand which types of individuals may be most responsive to exposure to basic vaccine information, we examine heterogeneity in treatment effects across demographic subgroups about which policymakers can conceivably obtain data at scale—and could thus microtarget campaign messaging towards. Specifically, we consider a respondent's sex, age category, highest level of completed education, socioeconomic class, and intention to vote for the President. Using the specifications described in S3 Appendix, Table S17 shows that the treatments produced similar effects on different types of hesitant respondent. The only systematic difference is that basic vaccine information is slightly more effective at persuading women to vaccinate than men.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Any vaccine information	0.343	0.136	0.109	−0.002
	(0.253)	(0.109)	(0.645)	(0.120)
Any vaccine information × Woman	0.028	0.039*	0.239**	0.014
	(0.050)	(0.021)	(0.120)	(0.025)
Any vaccine information × Aged 25-34	0.088	−0.010	−0.136	−0.021
	(0.074)	(0.032)	(0.169)	(0.038)
Any vaccine information × Aged 35-44	0.078	−0.007	−0.062	−0.056
	(0.076)	(0.033)	(0.184)	(0.041)
Any vaccine information × Aged 45-54	0.039	−0.032	−0.142	−0.022
	(0.083)	(0.034)	(0.189)	(0.040)
Any vaccine information × Aged 55-64	−0.057	−0.029	−0.590**	−0.029
	(0.094)	(0.039)	(0.254)	(0.044)
Any vaccine information × Aged 65+	0.097	−0.002	−0.217	0.015
	(0.092)	(0.039)	(0.201)	(0.044)
Any vaccine information × Middle SES	−0.120	−0.035	0.133	−0.010
	(0.097)	(0.037)	(0.213)	(0.044)
Any vaccine information × High SES	−0.083	−0.034	0.255	−0.016
	(0.091)	(0.034)	(0.206)	(0.042)
Any vaccine information × Would vote for President	0.081	0.008	0.010	0.004
	(0.065)	(0.025)	(0.141)	(0.028)
Any vaccine information × Primary education	0.053	−0.061	0.192	0.133
	(0.242)	(0.105)	(0.597)	(0.112)
Any vaccine information × Secondary education	−0.230	−0.111	−0.186	0.041
	(0.222)	(0.098)	(0.580)	(0.104)
Any vaccine information × University education	−0.266	−0.121	−0.169	0.060
	(0.225)	(0.099)	(0.586)	(0.105)
Any vaccine information × Other higher education	−0.197	−0.107	0.131	0.043
	(0.229)	(0.100)	(0.591)	(0.106)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.17	0.40	5.78	0.54
Control outcome std. dev	1.18	0.49	4.38	0.50
Observations	6,947	6,947	6,872	6,655
R^2	0.487	0.494	0.767	0.361

Table S17: Effect of any vaccine information on vaccine willingness, by pre-treatment covariate. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Lower-order interaction terms are omitted to save space; the omitted categories are aged 18-24, would not vote for the President, and university education. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S10 Heterogeneity in the effect of herd immunity information

We next examine the effect of herd immunity treatments that induced respondents to update their beliefs to different degrees and in different directions, relative to their prior beliefs. Using the specification described in S3 Appendix, column (1) first seeks to validate whether the herd immunity information altered respondents' posterior beliefs about the level of vaccination required to achieve herd immunity. Indeed, respondents whose prior beliefs were below (above) the expert opinion that they were exposed to updated their posterior beliefs upwards (downwards). Columns (2)-(5) then examine the effect of such updating on vaccine willingness, finding little evidence to suggest that respondents that updated their posterior beliefs in different ways adopted different stances toward vaccination. This finding is robust to considering herd immunity treatments that induced respondents to update positively or negatively (panel A) or more subtle forms degrees of updating relative to a control group that received information within 5 percentage points either side of their prior belief (panel B). The results ultimately suggest that learning about herd immunity rates on their own did not play a key role in explaining vaccine willingness.

	Outcome variable:				
	Posterior belief about rate required for herd immunity	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)	(5)
Panel A: Prior beliefs above/below reported expert herd rate					
Prior belief below reported herd rate	3.624***	0.060	−0.012	−0.007	−0.028
	(1.151)	(0.074)	(0.032)	(0.213)	(0.039)
Outcome range	[0-100]	[1-5]	{0,1}	[0,12]	{0,1}
Control outcome mean	84.02	3.57	0.55	7.22	0.69
Control outcome std. dev.	14.89	1.08	0.50	4.06	0.46
Observations	2,801	2,955	2,955	2,919	2,821
R^2	0.637	0.496	0.476	0.729	0.415
Panel B: Prior beliefs relative to reported expert herd rate					
Prior belief 5-15pp below reported herd rate	4.282**	0.020	−0.051	−0.220	0.012
	(1.881)	(0.115)	(0.046)	(0.295)	(0.059)
Prior belief 15pp below reported herd rate	6.933***	0.036	0.012	−0.078	−0.028
	(2.393)	(0.137)	(0.055)	(0.387)	(0.070)
Prior belief 5-15pp above reported herd rate	−1.192	−0.063	−0.005	−0.256	0.011
	(1.044)	(0.069)	(0.031)	(0.184)	(0.037)
Prior belief 15pp above reported herd rate	−3.871***	−0.049	0.045	−0.038	0.071*
	(1.289)	(0.082)	(0.039)	(0.230)	(0.043)
Outcome range	[0,100]	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	74.46	3.36	0.44	6.29	0.56
Control outcome std. dev.	12.66	1.10	0.50	4.28	0.50
Observations	2,801	2,955	2,955	2,919	2,821
R^2	0.638	0.496	0.477	0.729	0.416

Table S18: Effect of different types of different expert opinion herd immunity opinion on vaccine willingness, by how the information relates to individual prior beliefs. All specifications include country × block fixed effects, prior belief level fixed effects, and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. The sample is restricted to respondents that received a treatment that reported an expert herd immunity rate. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S11 Heterogeneity in the effect of current willingness information

While providing information about the current willingness of the population to get vaccinated does not affect vaccine willingness on average, this null finding may mask variation in responses that depends on the direction in which the information encouraged respondents to update their posterior beliefs about communal uptake rates. Indeed, the free riding logic suggests that individuals that come to believe that more (less) people will get vaccinated than they previously expected, will become less (more) willing to vaccinate themselves. In contrast, if individuals regard the intentions of others as informative about their own costs and benefits or seek to coordinate their behavior with that of others, then we should expect to observe the reverse relationship. Using the specification described in S3 Appendix, Table S19 detects no evidence to support either logic: respondents that were informed of a current willing that exceed their prior belief became no more or less willing to get vaccinated. As the main paper notes, this suggests that simple forms of free riding, social learning, or coordination are unlikely to be important drivers vaccine willingness.

	Outcome variable:				
	Posterior belief about rate municipal willingness (1)	Vaccine willingness scale (2)	Willing to take a vaccine (3)	Months would wait to get vaccinated (reversed) (4)	Encourage others to get vaccinated (5)
Panel A: Prior beliefs above/below current willingness					
Current	-1.491^{**}	0.043	0.024	0.253^{**}	0.026
	(0.623)	(0.042)	(0.017)	(0.108)	(0.017)
Prior below current willingness	-25.857^{***}	-0.180^{***}	-0.067^{***}	-0.291^{***}	-0.123^{***}
	(0.551)	(0.027)	(0.011)	(0.071)	(0.013)
Current × Prior below current willingness	3.296^{***}	0.021	-0.005	-0.091	-0.003
	(1.067)	(0.054)	(0.023)	(0.145)	(0.024)
Outcome range	[0,100]	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	61.81	3.17	0.40	5.78	0.54
Control outcome std. dev.	24.37	1.18	0.49	4.38	0.50
Observations	6,747	6,951	6,951	6,876	6,659
R^2	0.402	0.438	0.444	0.719	0.354
Panel B: Prior beliefs relative to current willingness					
Current	-0.184	0.029	0.047	0.078	0.065^{**}
	(1.002)	(0.064)	(0.030)	(0.150)	(0.031)
Prior 5-15pp below current willingness	5.917^{***}	0.079^{*}	0.041^{**}	0.190^{*}	0.044^{**}
	(0.748)	(0.044)	(0.019)	(0.106)	(0.021)
Prior 15pp below current willingness	14.594^{***}	0.059	0.040^{**}	0.100	0.075^{***}
	(0.788)	(0.047)	(0.019)	(0.115)	(0.021)
Prior 5-15pp above current willingness	-8.501^{***}	-0.060	-0.009	-0.050	-0.041^{*}
	(0.826)	(0.043)	(0.019)	(0.114)	(0.022)
Prior 15pp above current willingness	-26.520^{***}	-0.201^{***}	-0.060^{***}	-0.304^{***}	-0.110^{***}
	(0.782)	(0.038)	(0.017)	(0.099)	(0.020)
Current × Prior 5-15pp below current willingness	-0.687	-0.063	-0.046	0.263	-0.056
	(1.347)	(0.088)	(0.040)	(0.216)	(0.041)
Current × Prior 15pp below current willingness	-1.124	0.112	0.002	0.140	-0.028
	(1.383)	(0.099)	(0.042)	(0.245)	(0.041)
Current × Prior 5-15pp above current willingness	2.681^{*}	0.113	-0.025	0.148	-0.039
	(1.590)	(0.087)	(0.042)	(0.242)	(0.046)
Current × Prior 15pp above current willingness	2.622^{*}	0.013	-0.036	0.083	-0.050
	(1.534)	(0.077)	(0.035)	(0.198)	(0.038)
Outcome range	[0,100]	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	61.810	3.170	0.400	5.780	0.540
Control outcome std. dev.	24.370	1.180	0.490	4.380	0.500
Observations	6,747	6,951	6,951	6,876	6,659
R^2	0.510	0.442	0.447	0.720	0.360

Table S19: Effect of vaccine information on vaccine willingness, by how current willingness relates to individual prior beliefs. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. All treatments and associated interactions are included in panel B, but omitted to save space. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S12 Pre-treatment vaccine hesitancy and prior beliefs

As shown in the main paper, beliefs about the vaccination rates required to achieve herd immunity and the current level of willingness in the population appear to coordinate individuals in a more subtle way: respondents became more willing to get vaccinated when they learned that the population was on track to achieve herd immunity. While the results in the main paper demonstrate this experimentally, we conduct a further analysis based on respondents' prior beliefs to assess this logic correlationally before treatments were delivered. To do so, we examine the interaction between the two prior beliefs using the following OLS regression within our full sample (not just among hesitant respondents):

$$Y_{ic} = \beta_0 + \beta_1 Herd\ prior_{ic} + \beta_2 Willing\ prior_{ic} + \beta_3 (Herd\ prior_{ic} \times Willing\ prior_{ic}) + \varepsilon_{ic}. \quad (8)$$

The results, which are reported in Table S20 for the three outcomes measured before treatment, find a statistically significant positive interaction effect in each case. As with the experimental evidence, this suggests that individuals who believed—before treatment—that a given level of mass vaccination is required to achieve herd immunity were more willing to get vaccinated if they believe that many others are also likely to get vaccinated.

	Outcome variable:		
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)
Constant	1.920537^{***}	-0.006324	0.379705^{*}
	(0.067262)	(0.016529)	(0.229238)
Pre-treatment uptake rate	0.003240^{**}	0.000581	0.012471^{**}
	(0.001468)	(0.000414)	(0.004998)
Pre-treatment herd immunity	0.010004^{***}	0.001264^{***}	0.037189^{***}
	(0.000938)	(0.000289)	(0.003279)
Pre-treatment uptake $\times$ herd immunity	0.000032^{*}	0.000042^{***}	0.000288^{***}
	(0.000018)	(0.000006)	(0.000061)
Outcome range	[1,5]	$\{0,1\}$	[0,12]
Observations	7,521	7,521	7,521
R^2	0.105	0.099	0.177

Table S20: Correlation between prior beliefs and prior vaccine willingness. All specifications are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S13 Heterogeneity in the effect of motivational messages

To understand which types of individuals may be most responsive to different types of motivational message, we again examine heterogeneity in treatment effects across demographic subgroups about which policymakers could conceivably obtain data at scale—and could thus microtarget campaign messaging towards. Specifically, we consider a respondent's sex, age category, highest level of completed education, socioeconomic class, and intention to vote for the President. Estimating the specifications described in S3 Appendix, Table S21 shows that the treatments produced similar effects on different types of hesitant respondent. While there is some evidence to suggest that older respondents were less responsive to the social approval message, the effects are largely similar across types of respondent.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Altruism	−0.307	0.008	−0.138	−0.136
	(0.264)	(0.112)	(0.797)	(0.121)
Economic recovery	−0.179	−0.073	0.703	−0.343***
	(0.259)	(0.113)	(0.639)	(0.128)
Social Approval	0.067	0.219**	1.645**	−0.008
	(0.256)	(0.108)	(0.834)	(0.131)
Altruism × Woman	0.003	−0.010	0.054	−0.012
	(0.062)	(0.026)	(0.166)	(0.029)
Economic recovery × Woman	0.075	0.005	−0.035	−0.010
	(0.062)	(0.026)	(0.165)	(0.029)
Social status × Woman	0.057	−0.014	0.047	0.004
	(0.062)	(0.026)	(0.174)	(0.030)
Altruism × Aged 25-34	0.015	−0.037	0.041	−0.024
	(0.095)	(0.041)	(0.244)	(0.046)
Economic recovery × Aged 25-34	0.061	−0.038	−0.232	0.086*
	(0.095)	(0.041)	(0.237)	(0.046)
Social status × Aged 25-34	0.039	−0.038	0.525**	0.012
	(0.093)	(0.041)	(0.249)	(0.047)
Altruism × Aged 35-44	−0.030	−0.028	−0.009	0.005
	(0.093)	(0.041)	(0.273)	(0.048)
Economic recovery × Aged 35-44	−0.064	−0.056	−0.265	0.046
	(0.095)	(0.041)	(0.265)	(0.048)
Social status × Aged 35-44	−0.095	−0.052	0.358	−0.024
	(0.096)	(0.042)	(0.271)	(0.048)
Altruism × Aged 45-54	0.142	0.047	0.047	0.041
	(0.102)	(0.043)	(0.284)	(0.049)
Economic recovery × Aged 45-54	−0.053	−0.039	−0.346	0.028
	(0.103)	(0.042)	(0.282)	(0.048)
Social status × Aged 45-54	−0.038	−0.035	−0.020	0.003
	(0.103)	(0.042)	(0.295)	(0.049)
Altruism × Aged 55-64	0.127	0.016	0.180	−0.027
	(0.114)	(0.047)	(0.294)	(0.051)
Economic recovery × Aged 55-64	0.092	0.019	0.087	0.025
	(0.124)	(0.052)	(0.303)	(0.053)
Social status × Aged 55-64	0.082	0.019	0.374	−0.054
	(0.116)	(0.049)	(0.309)	(0.053)
Altruism × Aged 65+	−0.153	−0.053	−0.046	−0.024
	(0.118)	(0.050)	(0.294)	(0.053)
Economic recovery × Aged 65+	−0.079	−0.061	−0.575*	0.030
	(0.112)	(0.049)	(0.310)	(0.054)
Social status × Aged 65+	−0.106	−0.117**	−0.232	−0.028
	(0.114)	(0.048)	(0.303)	(0.054)
Altruism × Middle SES	0.105	0.010	0.413	0.012
	(0.124)	(0.049)	(0.293)	(0.052)
Economic recovery × Middle SES	0.101	0.033	0.255	0.035
	(0.128)	(0.049)	(0.286)	(0.052)
Social status × Middle SES	0.108	0.003	−0.076	0.087*
	(0.123)	(0.047)	(0.320)	(0.052)
Altruism × High SES	0.037	−0.016	0.304	0.033
	(0.119)	(0.046)	(0.271)	(0.049)
Economic recovery × High SES	0.107	0.035	0.191	0.038
	(0.122)	(0.046)	(0.264)	(0.049)
Social status × High SES	0.118	0.014	0.080	0.104**
	(0.119)	(0.045)	(0.304)	(0.049)
Altruism × Would vote for President	−0.024	−0.029	−0.008	−0.081**
	(0.082)	(0.033)	(0.214)	(0.035)
Economic recovery × Would vote for President	0.102	0.030	0.445**	0.026
	(0.085)	(0.034)	(0.222)	(0.036)
Social status × Would vote for President	0.014	−0.022	−0.225	−0.047
	(0.086)	(0.034)	(0.220)	(0.036)
Altruism × Primary education	0.078	0.011	−0.493	0.138
	(0.235)	(0.104)	(0.727)	(0.113)
Economic recovery × Primary education	−0.024	0.096	−0.790	0.352***
	(0.224)	(0.101)	(0.583)	(0.115)
Social status × Primary education	0.044	−0.081	−1.412*	0.023
	(0.224)	(0.099)	(0.755)	(0.121)
Altruism × Secondary education	0.273	0.041	−0.200	0.168*
	(0.210)	(0.093)	(0.684)	(0.099)
Economic recovery × Secondary education	−0.023	0.066	−0.793	0.328***
	(0.199)	(0.091)	(0.485)	(0.104)
Social status × Secondary education	−0.170	−0.144	−1.716**	−0.042
	(0.198)	(0.088)	(0.706)	(0.110)
Altruism × University education	0.295	0.059	−0.113	0.193*
	(0.212)	(0.095)	(0.685)	(0.100)
Economic recovery × University education	0.041	0.107	−0.702	0.273***
	(0.203)	(0.092)	(0.487)	(0.105)
Social status × University education	−0.086	−0.104	−1.695**	−0.011
	(0.202)	(0.089)	(0.712)	(0.111)
Altruism × Other higher education	0.219	0.030	−0.367	0.140
	(0.215)	(0.096)	(0.697)	(0.102)
Economic recovery × Other higher education	0.020	0.066	−0.670	0.330***
	(0.207)	(0.094)	(0.511)	(0.107)
Social status × Other higher education	−0.208	−0.125	−1.658**	−0.035
	(0.207)	(0.092)	(0.727)	(0.113)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.24	0.42	6.07	0.55
Control outcome std. dev	1.17	0.49	4.41	0.50
Observations	6,947	6,947	6,872	6,655
R^2	0.447	0.460	0.730	0.346

Table S21: Effect of any motivational messages on vaccine willingness, by pre-treatment covariate. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Lower-order interaction terms are omitted to save space. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S14 Interaction between informational and motivational messages

While both basic vaccine information and social approval messages proved effective at increasing vaccine willingness among hesitant respondents, it may be important from a policy perspective to understand whether these messages serve as substitutes or complements. To do so, we examine the interaction between the two treatment conditions, which were assigned independently. The results in Table S22 find no systematic evidence of a positive or negative interaction between any of the motivational messages and receiving basic vaccine information. This suggests that the two types of messaging campaigns may be largely additive.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Altruism	0.023	0.000	0.149	0.030
	(0.057)	(0.023)	(0.123)	(0.030)
Economic recovery	0.019	0.006	0.108	0.062**
	(0.055)	(0.023)	(0.119)	(0.029)
Social status	0.142**	0.056**	0.394***	0.075**
	(0.057)	(0.025)	(0.150)	(0.031)
Any vaccine information	0.143***	0.038**	0.511***	0.061**
	(0.045)	(0.019)	(0.115)	(0.025)
Altruism × Any vaccine information	0.001	0.019	−0.091	−0.016
	(0.068)	(0.028)	(0.157)	(0.035)
Economic recovery × Any vaccine information	0.045	0.021	−0.147	−0.040
	(0.066)	(0.028)	(0.154)	(0.034)
Social status × Any vaccine information	−0.048	−0.013	−0.171	−0.040
	(0.068)	(0.029)	(0.181)	(0.036)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.16	0.40	5.71	0.51
Control outcome std. dev.	1.15	0.49	4.28	0.50
Observations	6,951	6,951	6,876	6,659
R^2	0.485	0.493	0.767	0.358

Table S22: Effect of any vaccine information on vaccine willingness, by motivational message. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S15 Effects on encouraging others to vaccinate measured as a scale

In the paper we examine willingness to encourage others to get vaccinated using a binary variable that focuses on those that are likely or very likely do so. Tables S23-S25 show that similar results hold for the underlying four-point scale. While the ordinal measure is more fine-grained, it also assumes that each unit increase in the outcome captures a similar change.

	Outcome variable: Encourage others to get vaccinated scale (1)
Panel A: All countries pooled	
Any vaccine information	0.094***
	(0.023)
Outcome range	{1,2,3,4}
Control outcome mean	2.56
Control outcome std. dev	1.01
Observations	6,659
R^2	0.417
Panel B: Argentina	
Any vaccine information	0.073
	(0.056)
Outcome range	{1,2,3,4}
Control outcome mean	2.44
Control outcome std. dev	0.99
Observations	1,109
R^2	0.389
Panel C: Brazil	
Any vaccine information	0.079
	(0.058)
Outcome range	{1,2,3,4}
Control outcome mean	2.45
Control outcome std. dev	1.12
Observations	1,134
R^2	0.483
Panel D: Chile	
Any vaccine information	0.155**
	(0.060)
Outcome range	{1,2,3,4}
Control outcome mean	2.37
Control outcome std. dev	1.06
Observations	1,080
R^2	0.418
Panel E: Colombia	
Any vaccine information	0.129**
	(0.052)
Outcome range	{1,2,3,4}
Control outcome mean	2.64
Control outcome std. dev	0.97
Observations	1,085
R^2	0.447
Panel F: México	
Any vaccine information	0.105*
	(0.055)
Outcome range	{1,2,3,4}
Control outcome mean	2.80
Control outcome std. dev	0.93
Observations	1,075
R^2	0.367
Panel G: Perú	
Any vaccine information	0.026
	(0.053)
Outcome range	{1,2,3,4}
Control outcome mean	2.63
Control outcome std. dev	0.91
Observations	1,176
R^2	0.342

Table S23: Effect of any vaccine information on willingness to encourage others to get vaccinated scale. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable: Encourage others to get vaccinated scale (1)
Vaccine	0.083^{***}
	(0.030)
Vaccine + Herd 60%	0.081^{*}
	(0.042)
Vaccine + Herd 70%	0.100^{**}
	(0.043)
Vaccine + Herd 80%	0.080^{*}
	(0.043)
Vaccine + Herd 60% + Current	0.160^{***}
	(0.041)
Vaccine + Herd 70% + Current	0.116^{***}
	(0.042)
Vaccine + Herd 80% + Current	0.062
	(0.042)
Vaccine + Biden	0.090^{***}
	(0.035)
Outcome range	{1,2,3,4}
Control outcome mean	2.56
Control outcome std. dev	1.01
Observations	6,659
R^2	0.397

Table S24: Effect of different types of vaccine information treatment on willingness to encourage others to get vaccinated scale. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable: Encourage others to get vaccinated scale (1)
Panel A: All countries pooled	
Altruism	0.029
	(0.028)
Economic recovery	0.043
	(0.028)
Social approval	0.080***
	(0.028)
Outcome range	{1,2,3,4}
Control outcome mean	2.60
Control outcome std. dev	1.01
Observations	6,659
R^2	0.395
Panel B: Argentina	
Altruism	0.012
	(0.069)
Economic recovery	0.006
	(0.067)
Social approval	0.031
	(0.071)
Outcome range	{1,2,3,4}
Control outcome mean	2.52
Control outcome std. dev	0.98
Observations	1,109
R^2	0.374
Panel C: Brazil	
Altruism	0.022
	(0.066)
Economic recovery	0.001
	(0.068)
Social approval	0.095
	(0.064)
Outcome range	{1,2,3,4}
Control outcome mean	2.48
Control outcome std. dev	1.08
Observations	1,134
R^2	0.475
Panel D: Chile	
Altruism	0.078
	(0.074)
Economic recovery	0.103
	(0.071)
Social approval	0.094
	(0.074)
Outcome range	{1,2,3,4}
Control outcome mean	2.48
Control outcome std. dev	1.06
Observations	1,080
R^2	0.390
Panel E: Colombia	
Altruism	0.132**
	(0.064)
Economic recovery	0.062
	(0.064)
Social approval	0.107*
	(0.063)
Outcome range	{1,2,3,4}
Control outcome mean	2.65
Control outcome std. dev	0.94
Observations	1,085
R^2	0.411
Panel F: México	
Altruism	0.030
	(0.069)
Economic recovery	0.064
	(0.070)
Social approval	0.075
	(0.070)
Outcome range	{1,2,3,4}
Control outcome mean	2.84
Control outcome std. dev	0.96
Observations	1,075
R^2	0.344
Panel G: Perú	
Altruism	−0.091
	(0.069)
Economic recovery	0.029
	(0.068)
Social approval	0.086
	(0.070)
Outcome range	{1,2,3,4}
Control outcome mean	2.63
Control outcome std. dev	0.97
Observations	1,176
R^2	0.328

Table S25: Effect of different types of motivational message on willingness to encourage others to get vaccinated scale. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S16 Demand for further information

The main paper focused on vaccine willingness in terms of intentions to act get vaccinated and encourage others to get vaccinated. To examine a less direct behavioral outcome, we also report the effects of the treatments on interest in receiving additional information COVID-19 vaccines from the Pan American Health Organization. Tables S26-S28 report the effects of the information and motivational treatments on seeking such information. In each case, we find little evidence to suggest that the treatments moved interest in receiving further information. It should be noted that this opportunity came after a 25 minute survey that already provided treated respondents with considerable vaccine information already. The null effects could then be explained by treated respondents already feeling sufficiently informed about COVID-19 vaccines that they did not need to expend additional effort to acquire further information.

	Outcome variable:	
	Requested more information (1)	Visited PAHO website (2)
Panel A: All countries pooled		
Any vaccine information	−0.020	0.001
	(0.015)	(0.012)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.57	0.22
Control outcome std. dev.	0.50	0.42
Observations	6,082	6,082
R^2	0.107	0.097
Panel B: Argentina		
Any vaccine information	0.008	0.041
	(0.037)	(0.028)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.48	0.19
Control outcome std. dev.	0.50	0.40
Observations	1,019	1,019
R^2	0.088	0.161
Panel C: Brazil		
Any vaccine information	−0.006	0.012
	(0.038)	(0.029)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.49	0.19
Control outcome std. dev.	0.50	0.39
Observations	1,007	1,007
R^2	0.054	0.060
Panel D: Chile		
Any vaccine information	−0.020	0.046
	(0.036)	(0.030)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.52	0.18
Control outcome std. dev.	0.50	0.38
Observations	1,006	1,006
R^2	0.110	0.088
Panel E: Colombia		
Any vaccine information	−0.033	−0.029
	(0.035)	(0.032)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.62	0.25
Control outcome std. dev.	0.48	0.44
Observations	1,011	1,011
R^2	0.101	0.080
Panel F: México		
Any vaccine information	−0.039	−0.050
	(0.036)	(0.031)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.62	0.26
Control outcome std. dev.	0.49	0.44
Observations	1,005	1,005
R^2	0.085	0.100
Panel G: Perú		
Any vaccine information	−0.031	−0.016
	(0.033)	(0.032)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.68	0.27
Control outcome std. dev.	0.46	0.45
Observations	1,034	1,034
R^2	0.114	0.093

Table S26: Effect of any vaccine information on demand for further vaccine information. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:	
	Requested more information	Visited PAHO website
	(1)	(2)
Vaccine	−0.009	0.012
	(0.019)	(0.017)
Vaccine + Biden	−0.027	−0.014
	(0.022)	(0.018)
Vaccine + Herd 60%	−0.021	−0.001
	(0.027)	(0.023)
Vaccine + Herd 70%	−0.003	0.020
	(0.026)	(0.023)
Vaccine + herd 80%	−0.024	−0.018
	(0.027)	(0.022)
Vaccine + Herd 60% + Current	−0.034	0.002
	(0.027)	(0.023)
Vaccine + Herd 70% + Current	−0.025	−0.012
	(0.027)	(0.022)
Vaccine + Herd 80% + Current	−0.037	−0.005
	(0.027)	(0.022)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.57	0.22
Control outcome std. dev.	0.50	0.42
Observations	6,082	6,082
R^2	0.101	0.098

Table S27: Effect of different types of vaccine information treatment on demand for further vaccine information. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:	
	Requested more information	Visited PAHO website
	(1)	(2)
Panel A: All countries pooled		
Altruism	−0.009	−0.027*
	(0.017)	(0.015)
Economic recovery	−0.014	−0.028*
	(0.018)	(0.015)
Social approval	0.014	−0.006
	(0.018)	(0.015)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.56	0.24
Control outcome std. dev.	0.50	0.43
Observations	6,082	6,082
R^2	0.097	0.090
Panel B: Argentina		
Altruism	0.014	−0.043
	(0.043)	(0.036)
Economic recovery	−0.000	−0.023
	(0.045)	(0.037)
Social approval	0.021	−0.026
	(0.043)	(0.036)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.49	0.26
Control outcome std. dev.	0.50	0.44
Observations	1,019	1,019
R^2	0.085	0.135
Panel C: Brazil		
Altruism	−0.089**	−0.051
	(0.044)	(0.033)
Economic recovery	−0.057	−0.011
	(0.044)	(0.034)
Social approval	0.017	0.060
	(0.044)	(0.037)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.51	0.19
Control outcome std. dev.	0.50	0.39
Observations	1,007	1,007
R^2	0.063	0.074
Panel D: Chile		
Altruism	−0.009	0.012
	(0.044)	(0.037)
Economic recovery	−0.018	−0.030
	(0.044)	(0.036)
Social approval	0.043	0.010
	(0.044)	(0.037)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.51	0.23
Control outcome std. dev.	0.50	0.42
Observations	1,006	1,006
R^2	0.094	0.097
Panel E: Colombia		
Altruism	0.039	−0.010
	(0.043)	(0.038)
Economic recovery	0.081*	−0.023
	(0.043)	(0.037)
Social approval	0.087**	−0.021
	(0.043)	(0.037)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.54	0.25
Control outcome std. dev.	0.50	0.43
Observations	1,011	1,011
R^2	0.087	0.068
Panel F: México		
Altruism	0.051	0.000
	(0.043)	(0.037)
Economic recovery	−0.033	−0.036
	(0.044)	(0.036)
Social approval	−0.014	−0.006
	(0.043)	(0.036)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.58	0.22
Control outcome std. dev.	0.49	0.42
Observations	1,005	1,005
R^2	0.086	0.084
Panel G: Perú		
Altruism	−0.061	−0.071*
	(0.040)	(0.038)
Economic recovery	−0.058	−0.043
	(0.040)	(0.038)
Social approval	−0.068*	−0.050
	(0.040)	(0.039)
Outcome range	{0,1}	{0,1}
Control outcome mean	0.71	0.30
Control outcome std. dev.	0.46	0.46
Observations	1,034	1,034
R^2	0.105	0.092

Table S28: Effect of different types of motivational message on demand for further vaccine information. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space) and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S17 Population-weighted treatment effects

In estimating treatment effects, we did not apply population weights for each respondent to maximize the efficiency of our estimation of average treatment effects within a sample that was already nationally representative along several key dimensions. To more thoroughly examine how the results extend to the national hesitant population, we further weight our estimates in two ways (taking the product of inverse probability of treatment assignment weights and population weights, wherever relevant). First, within each country, we weight each respondent according to the relative frequency in the survey of the respondent's cell—defined by their age category, education, region, and gender—relative to the corresponding cell in the most recent available census. In other words, we reweight observations according to the joint distribution over these four variables in the population. Second, we instead apply rake weights to reweight observations according to the product of in-survey marginal distribution, relative to the national distribution, across the following variables: age category, education, region, gender, and (using data provided by Netquest) socioeconomic class. In each case, a small number of observations are dropped because weights could not be defined.

The results in Tables S29-S36 show that similar results apply. If anything, the positive effects of basic vaccine information on vaccine willingness and encouraging others are larger in magnitude once the population distribution is taken into account, although the effect on expected wait until vaccination once eligible is a little lower. The effects of the social approval treatment are also a little larger in magnitude. Unsurprisingly, the standard errors become larger once each type of weight is applied, although the core findings generally remain statistically significant for each type of population weight.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Any vaccine information	0.170***	0.067***	0.348***	0.055***
	(0.037)	(0.015)	(0.087)	(0.018)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.14	0.38	5.84	0.50
Control outcome std. dev.	1.20	0.49	4.35	0.50
Observations	6,922	6,922	6,847	6,631
R^2	0.506	0.505	0.773	0.389
Panel B: Argentina				
Any vaccine information	0.268***	0.075*	0.473**	0.083*
	(0.094)	(0.042)	(0.216)	(0.046)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	2.90	0.32	4.56	0.37
Control outcome std. dev.	1.12	0.47	4.42	0.48
Observations	1,156	1,156	1,146	1,105
R^2	0.489	0.511	0.824	0.424
Panel C: Brazil				
Any vaccine information	0.315***	0.126***	0.427**	0.035
	(0.077)	(0.033)	(0.180)	(0.038)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.15	0.35	5.87	0.43
Control outcome std. dev.	1.19	0.48	4.31	0.50
Observations	1,212	1,212	1,186	1,133
R^2	0.593	0.531	0.764	0.439
Panel D: Chile				
Any vaccine information	0.153	0.070**	0.397*	0.086**
	(0.095)	(0.036)	(0.218)	(0.040)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	2.94	0.32	4.97	0.43
Control outcome std. dev.	1.28	0.47	4.26	0.49
Observations	1,109	1,109	1,101	1,076
R^2	0.528	0.537	0.791	0.425
Panel E: Colombia				
Any vaccine information	0.226***	0.094***	0.441***	0.077*
	(0.082)	(0.032)	(0.143)	(0.040)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.13	0.37	6.21	0.55
Control outcome std. dev.	1.24	0.48	4.28	0.50
Observations	1,130	1,130	1,119	1,084
R^2	0.506	0.526	0.834	0.408
Panel F: México				
Any vaccine information	−0.001	0.003	0.160	−0.002
	(0.099)	(0.043)	(0.224)	(0.050)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.60	0.55	7.32	0.69
Control outcome std. dev.	1.20	0.50	4.03	0.46
Observations	1,098	1,098	1,094	1,071
R^2	0.453	0.470	0.692	0.284
Panel G: Perú				
Any vaccine information	0.062	0.031	0.195	0.052
	(0.085)	(0.036)	(0.263)	(0.044)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.14	0.40	6.27	0.55
Control outcome std. dev.	1.06	0.49	4.22	0.50
Observations	1,217	1,217	1,201	1,162
R^2	0.422	0.440	0.686	0.299

Table S29: Effect of any vaccine information on vaccine willingness, using population cell weights. All specifications include country $\times$ block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Vaccine	0.122**	0.053**	0.276**	0.060**
	(0.054)	(0.022)	(0.119)	(0.025)
Vaccine + Biden	0.205***	0.090***	0.382**	0.080***
	(0.065)	(0.029)	(0.168)	(0.031)
Vaccine + Herd 60%	0.117*	0.048	0.211	0.028
	(0.067)	(0.029)	(0.168)	(0.035)
Vaccine + Herd 70%	0.202***	0.077***	0.561***	0.064**
	(0.072)	(0.029)	(0.162)	(0.032)
Vaccine + Herd 80%	0.161**	0.075**	0.313*	0.037
	(0.073)	(0.033)	(0.188)	(0.034)
Vaccine + Herd 60% + Current	0.229***	0.100***	0.441**	0.128***
	(0.067)	(0.032)	(0.218)	(0.031)
Vaccine + Herd 70% + Current	0.203***	0.081***	0.354**	0.092***
	(0.073)	(0.031)	(0.174)	(0.035)
Vaccine + Herd 80% + Current	0.150*	0.044	0.307*	−0.019
	(0.081)	(0.031)	(0.180)	(0.036)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.14	0.38	5.84	0.50
Control outcome std. dev.	1.20	0.49	4.35	0.50
Observations	6,922	6,922	6,847	6,631
R^2	0.452	0.448	0.722	0.358

Table S30: Effect of different types of vaccine information on vaccine willingness, using population cell weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Current	0.083	0.075*	0.256	0.110**
	(0.082)	(0.040)	(0.253)	(0.043)
Current rate below herd opinion	−0.001	0.023	0.026	0.012
	(0.073)	(0.035)	(0.211)	(0.041)
Current × Current rate below herd opinion	−0.060	−0.092*	−0.323	−0.118**
	(0.106)	(0.050)	(0.300)	(0.056)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.39	0.48	6.16	0.54
Control outcome std. dev.	1.16	0.50	4.35	0.50
Observations	2,943	2,943	2,907	2,809
R^2	0.503	0.476	0.730	0.407

Table S31: The effect of being informed that the current rate of vaccination willingness in the population is above/below the rate required for herd immunity, using population cell weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Altruism	−0.002	0.003	0.119	−0.007
	(0.050)	(0.021)	(0.120)	(0.024)
Economic recovery	0.051	0.020	−0.020	0.026
	(0.045)	(0.020)	(0.116)	(0.022)
Social approval	0.143***	0.062***	0.339***	0.048**
	(0.045)	(0.021)	(0.130)	(0.023)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.20	0.41	5.96	0.53
Control outcome std. dev.	1.16	0.49	4.42	0.50
Observations	6,922	6,922	6,847	6,631
R^2	0.453	0.457	0.734	0.349
Panel B: Argentina				
Altruism	−0.012	−0.011	0.247	−0.008
	(0.105)	(0.056)	(0.345)	(0.064)
Economic recovery	0.257**	0.117**	−0.047	0.054
	(0.116)	(0.059)	(0.309)	(0.062)
Social approval	0.189*	0.053	0.059	0.030
	(0.104)	(0.056)	(0.282)	(0.065)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.07	0.37	5.45	0.47
Control outcome std. dev.	1.07	0.48	4.37	0.50
Observations	1,156	1,156	1,146	1,105
R^2	0.452	0.451	0.797	0.365
Panel C: Brazil				
Altruism	−0.083	−0.038	0.564**	0.021
	(0.120)	(0.054)	(0.277)	(0.053)
Economic recovery	0.101	−0.004	0.921***	0.039
	(0.088)	(0.042)	(0.264)	(0.048)
Social approval	0.144*	0.068*	1.044***	0.055
	(0.084)	(0.040)	(0.267)	(0.048)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.30	0.42	5.24	0.45
Control outcome std. dev.	1.22	0.49	4.57	0.50
Observations	1,212	1,212	1,186	1,133
R^2	0.562	0.518	0.717	0.390
Panel D: Chile				
Altruism	0.159	0.080*	0.212	0.004
	(0.124)	(0.041)	(0.246)	(0.052)
Economic recovery	−0.012	0.041	0.100	0.035
	(0.104)	(0.038)	(0.255)	(0.053)
Social approval	0.187*	0.148***	0.836**	0.079
	(0.113)	(0.048)	(0.342)	(0.051)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	2.97	0.30	4.81	0.49
Control outcome std. dev.	1.15	0.46	4.37	0.50
Observations	1,109	1,109	1,101	1,076
R^2	0.479	0.490	0.746	0.379
Panel E: Colombia				
Altruism	−0.067	−0.019	0.562**	0.025
	(0.111)	(0.041)	(0.225)	(0.047)
Economic recovery	0.019	−0.016	−0.080	−0.003
	(0.106)	(0.045)	(0.202)	(0.049)
Social approval	0.210*	0.052	0.399	0.073
	(0.115)	(0.047)	(0.277)	(0.052)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.18	0.42	6.15	0.55
Control outcome std. dev.	1.25	0.49	4.62	0.50
Observations	1,130	1,130	1,119	1,084
R^2	0.461	0.465	0.780	0.360
Panel F: México				
Altruism	−0.032	−0.013	0.099	0.011
	(0.123)	(0.061)	(0.254)	(0.070)
Economic recovery	−0.125	−0.034	−0.109	0.047
	(0.120)	(0.054)	(0.356)	(0.058)
Social approval	0.018	−0.029	0.123	0.037
	(0.117)	(0.057)	(0.301)	(0.060)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.64	0.59	7.51	0.66
Control outcome std. dev.	1.07	0.49	3.70	0.48
Observations	1,098	1,098	1,094	1,071
R^2	0.373	0.415	0.651	0.275
Panel G: Perú				
Altruism	−0.002	0.016	−0.961***	−0.095
	(0.124)	(0.052)	(0.362)	(0.062)
Economic recovery	0.071	0.022	−0.910***	−0.010
	(0.113)	(0.049)	(0.290)	(0.056)
Social approval	0.131	0.071	−0.456	0.025
	(0.123)	(0.056)	(0.373)	(0.057)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.08	0.37	6.73	0.59
Control outcome std. dev.	1.10	0.48	4.25	0.49
Observations	1,217	1,217	1,201	1,162
R^2	0.368	0.399	0.685	0.308

Table S32: Effect of different types of motivational message on vaccine willingness, using population cell weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by population weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Any vaccine information	0.168***	0.051***	0.347***	0.020
	(0.039)	(0.016)	(0.099)	(0.020)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.17	0.41	6.02	0.54
Control outcome std. dev.	1.19	0.49	4.33	0.50
Observations	6,803	6,803	6,732	6,519
R^2	0.496	0.510	0.768	0.377
Panel B: Argentina				
Any vaccine information	0.253**	0.058	0.405**	0.089**
	(0.103)	(0.039)	(0.197)	(0.041)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	2.92	0.35	5.06	0.43
Control outcome std. dev.	1.22	0.48	4.46	0.49
Observations	1,130	1,130	1,120	1,081
R^2	0.473	0.498	0.834	0.440
Panel C: Brazil				
Any vaccine information	0.233***	0.092***	0.392*	0.003
	(0.072)	(0.033)	(0.214)	(0.036)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.24	0.40	5.93	0.49
Control outcome std. dev.	1.17	0.49	4.39	0.50
Observations	1,195	1,195	1,172	1,119
R^2	0.560	0.515	0.728	0.403
Panel D: Chile				
Any vaccine information	0.134	0.064*	0.473**	0.051
	(0.084)	(0.035)	(0.201)	(0.041)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	2.91	0.31	4.83	0.46
Control outcome std. dev.	1.21	0.46	4.42	0.50
Observations	1,085	1,085	1,077	1,052
R^2	0.500	0.472	0.785	0.337
Panel E: Colombia				
Any vaccine information	0.138*	0.060**	0.360***	0.054
	(0.073)	(0.029)	(0.131)	(0.039)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.17	0.39	6.19	0.54
Control outcome std. dev.	1.24	0.49	4.23	0.50
Observations	1,109	1,109	1,098	1,063
R^2	0.509	0.543	0.839	0.417
Panel F: México				
Any vaccine information	0.160	0.032	0.183	−0.058
	(0.112)	(0.042)	(0.288)	(0.057)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.51	0.54	7.30	0.70
Control outcome std. dev.	1.15	0.50	3.89	0.46
Observations	1,072	1,072	1,069	1,046
R^2	0.467	0.542	0.715	0.347
Panel G: Perú				
Any vaccine information	0.096	0.017	0.371	0.039
	(0.078)	(0.036)	(0.237)	(0.042)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.11	0.40	6.08	0.55
Control outcome std. dev.	1.04	0.49	4.27	0.50
Observations	1,212	1,212	1,196	1,158
R^2	0.421	0.432	0.695	0.310

Table S33: Effect of any vaccine information on vaccine willingness, using population rake weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population rake weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Vaccine	0.113*	0.042*	0.388***	0.051**
	(0.058)	(0.023)	(0.143)	(0.025)
Vaccine + Biden	0.179***	0.048*	0.165	−0.008
	(0.063)	(0.026)	(0.179)	(0.035)
Vaccine + Herd 60%	0.121*	0.043	0.115	0.012
	(0.070)	(0.037)	(0.173)	(0.040)
Vaccine + Herd 70%	0.177**	0.063*	0.560***	0.042
	(0.070)	(0.033)	(0.208)	(0.034)
Vaccine + Herd 80%	0.182***	0.053*	0.166	−0.028
	(0.068)	(0.029)	(0.157)	(0.037)
Vaccine + Herd 60% + Current	0.184***	0.068**	0.330	0.083***
	(0.065)	(0.030)	(0.208)	(0.032)
Vaccine + Herd 70% + Current	0.175**	0.062**	0.403**	0.057
	(0.070)	(0.031)	(0.174)	(0.036)
Vaccine + Herd 80% + Current	0.182**	0.038	0.592***	−0.004
	(0.079)	(0.029)	(0.221)	(0.034)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.17	0.41	6.02	0.54
Control outcome std. dev.	1.19	0.49	4.33	0.50
Observations	6,803	6,803	6,732	6,519
R^2	0.455	0.457	0.725	0.357

Table S34: Effect of different types of vaccine information on vaccine willingness, using population rake weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population rake weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale	Willing to take a vaccine	Months would wait to get vaccinated (reversed)	Encourage others to get vaccinated
	(1)	(2)	(3)	(4)
Current	0.076	0.066	0.295	0.066
	(0.081)	(0.042)	(0.220)	(0.046)
Current rate below herd opinion	0.054	0.043	0.165	−0.006
	(0.074)	(0.039)	(0.177)	(0.048)
Current × Current rate below herd opinion	−0.084	−0.093*	−0.243	−0.066
	(0.103)	(0.052)	(0.267)	(0.059)
Outcome range	[1,5]	{0,1}	[0,12]	{0,1}
Control outcome mean	3.37	0.48	6.32	0.53
Control outcome std. dev.	1.14	0.50	4.3	0.50
Observations	2,899	2,899	2,865	2,770
R^2	0.508	0.483	0.724	0.403

Table S35: The effect of being informed that the current rate of vaccination willingness in the population is above/below the rate required for herd immunity, using population rake weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by the inverse probability of treatment assignment and population rake weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

	Outcome variable:			
	Vaccine willingness scale (1)	Willing to take a vaccine (2)	Months would wait to get vaccinated (reversed) (3)	Encourage others to get vaccinated (4)
Panel A: All countries pooled				
Altruism	0.016	−0.002	0.087	−0.011
	(0.049)	(0.021)	(0.117)	(0.024)
Economic recovery	0.061	0.010	−0.017	0.051**
	(0.047)	(0.020)	(0.123)	(0.023)
Social approval	0.172***	0.043**	0.297**	0.020
	(0.052)	(0.022)	(0.140)	(0.024)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.24	0.43	6.28	0.56
Control outcome std. dev.	1.17	0.50	4.39	0.50
Observations	6,803	6,803	6,732	6,519
R^2	0.452	0.466	0.737	0.348
Panel B: Argentina				
Altruism	−0.146	−0.073	0.080	−0.045
	(0.117)	(0.055)	(0.252)	(0.061)
Economic recovery	0.239*	0.084	0.041	0.083
	(0.130)	(0.058)	(0.274)	(0.058)
Social approval	0.142	0.022	0.163	−0.006
	(0.123)	(0.058)	(0.282)	(0.061)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.07	0.37	5.56	0.48
Control outcome std. dev.	1.08	0.48	4.42	0.50
Observations	1,130	1,130	1,120	1,081
R^2	0.417	0.437	0.805	0.371
Panel C: Brazil				
Altruism	−0.115	−0.034	0.364	−0.021
	(0.085)	(0.038)	(0.261)	(0.042)
Economic recovery	0.087	0.024	0.782***	0.035
	(0.075)	(0.034)	(0.237)	(0.042)
Social approval	0.188**	0.085**	1.111***	0.043
	(0.080)	(0.037)	(0.286)	(0.045)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.31	0.41	5.45	0.46
Control outcome std. dev.	1.22	0.49	4.58	0.50
Observations	1,195	1,195	1,172	1,119
R^2	0.559	0.523	0.693	0.377
Panel D: Chile				
Altruism	0.148	0.077*	0.089	0.025
	(0.110)	(0.043)	(0.248)	(0.052)
Economic recovery	0.094	0.068	0.210	0.080
	(0.112)	(0.044)	(0.300)	(0.052)
Social approval	0.156	0.114**	0.628**	0.088*
	(0.103)	(0.045)	(0.312)	(0.051)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.01	0.32	5.11	0.49
Control outcome std. dev.	1.16	0.47	4.49	0.50
Observations	1,085	1,085	1,077	1,052
R^2	0.456	0.447	0.733	0.313
Panel E: Colombia				
Altruism	−0.003	0.028	0.676***	0.050
	(0.108)	(0.042)	(0.210)	(0.047)
Economic recovery	0.037	0.015	0.034	0.039
	(0.094)	(0.038)	(0.185)	(0.046)
Social approval	0.133	0.027	0.259	0.059
	(0.094)	(0.039)	(0.247)	(0.049)
Outcome range	1-5	0-1	0-12	0-1
Control outcome mean	3.26	0.42	6.36	0.56
Control outcome std. dev.	1.20	0.49	4.49	0.50
Observations	1,109	1,109	1,098	1,063
R^2	0.458	0.480	0.791	0.360
Panel F: México				
Altruism	0.172	0.010	0.249	0.003
	(0.139)	(0.061)	(0.283)	(0.071)
Economic recovery	−0.065	−0.069	−0.137	0.038
	(0.130)	(0.053)	(0.346)	(0.063)
Social approval	0.285*	0.020	0.387	−0.049
	(0.150)	(0.058)	(0.350)	(0.063)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.49	0.59	7.55	0.70
Control outcome std. dev.	1.20	0.49	3.81	0.46
Observations	1,072	1,072	1,069	1,046
R^2	0.433	0.499	0.721	0.364
Panel G: Perú				
Altruism	−0.057	−0.024	−1.044***	−0.075
	(0.107)	(0.051)	(0.364)	(0.057)
Economic recovery	0.034	−0.020	−1.014***	0.043
	(0.095)	(0.049)	(0.326)	(0.054)
Social approval	0.041	0.006	−0.818**	0.050
	(0.109)	(0.052)	(0.390)	(0.056)
Outcome range	[1,5]	{0,1}	[1,12]	{0,1}
Control outcome mean	3.14	0.40	6.95	0.57
Control outcome std. dev.	1.09	0.49	4.20	0.50
Observations	1,212	1,212	1,196	1,158
R^2	0.355	0.384	0.681	0.297

Table S36: Effect of different types of motivational message on vaccine willingness, using population rake weights. All specifications include country × block fixed effects and (standardized) pre-treatment wait until vaccination as covariates (omitted to save space), weight observations by population rake weights, and are estimated using OLS. Robust standard errors are in parentheses. * denotes $p < 0.1$, ** denotes $p < 0.05$, *** denotes $p < 0.01$ from two-sided t tests.

S18 Full survey questionnaire

Below we include the full survey instrument in Spanish. The Portuguese translation is available upon request. English translations for the information treatment conditions, motivation treatment conditions, and main outcome variables are, respectively, provided in sections S2, S2, and S5.

COLUMBIA UNIVERSITY
Institute for Social and Economic Research and Policy

Introduction

¡Hola!

Nos gustaría invitarlo a **participar en una encuesta para entender qué piensa la gente sobre la pandemia COVID-19**. Este estudio está siendo liderado por un grupo de investigadores de la Universidad de Columbia, Estados Unidos. Si usted desea participar, la encuesta le tomará aproximadamente **20 minutos**.

Su participación en el estudio es voluntaria. Además, una vez que termine la encuesta, la empresa Netquest lo recompensará. Sus respuestas se mantendrán estrictamente confidenciales. Usted puede terminar la encuesta en cualquier momento.

En caso de que tenga cualquier pregunta, duda, queja o comentario sobre este estudio, por favor contacte a John Marshall de la Universidad de Columbia, cuyo correo electrónico es jm4401@columbia.edu. Si tiene preguntas sobre sus derechos como sujeto de investigación, puede contactar al Comité de Ética Institucional de la Universidad de Columbia en el teléfono número +1 212 305 5883 o por correo electrónico askirboffice@columbia.edu.

Si desea participar en este estudio, haga click en el botón a continuación.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Screening/willingness questions

¿Hasta qué punto está usted de acuerdo o en desacuerdo?

Si una vacuna contra el COVID-19 estuviera disponible, yo me vacunaría.

- ○ Muy en desacuerdo
- ○ En desacuerdo
- ○ Ni de acuerdo ni en desacuerdo
- ○ De acuerdo
- ○ Muy de acuerdo
- ○ No estoy seguro

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para usted ahora, ¿cuántos meses esperaría antes de vacunarse?

- ○ [ ] Numero de meses:
- ○ Nunca tomaría una vacuna

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para todos ahora, ¿aproximadamente qué porcentaje de personas de su municipio piensa que se vacunarían?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para todos ahora, ¿aproximadamente qué porcentaje de personas de su municipio piensa que se vacunarían **durante los primeros dos meses de su disponibilidad**?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Quota questions

¿Cuál es su edad? (años cumplidos)

¿En qué municipio vive usted?

Estado

Municipio

¿Cuál fue el último año de enseñanza que usted completó o aprobó?

Nivel de educación

Años completados o aprobados en este nivel

¿Cuál es su género?

- Femenino
- Masculino
- Otro

Background and attention questions

¿Su hogar tiene electricidad, agua corriente, o drenaje? Seleccione todas las que correspondan.

- [ ] Drenaje
- [ ] Electricidad
- [ ] Agua Corriente
- [ ] Ninguna

¿Cuál es su religión?

- Católico
- Protestante, Protestante Tradicional, o Protestante no Evangélico
- Evangélico o Pentecostal
- Islam
- Hinduista
- Budista
- Religiones Tradicionales o Nativas
- Ninguna
- Agnóstico o ateo
- Otra:

¿Cuál es la ciudad capital de ${e://Field/country}?

- Brasília
- Santiago
- Bogotá
- Buenos Aires
- Lima
- Ciudad de México

Pre-treatment questions

¿Con qué frecuencia consume **noticias sobre COVID-19** de las siguientes fuentes?

	Nunca	Una vez cada dos meses	Una vez al mes	Una vez cada dos semanas	Una vez por semana	Varias veces por semana	Diariamente
Periódicos	○	○	○	○	○	○	○
Televisión	○	○	○	○	○	○	○
Radio	○	○	○	○	○	○	○
Conversaciones con otros	○	○	○	○	○	○	○
WhatsApp	○	○	○	○	○	○	○
Redes sociales (e.j. Facebook, Twitter)	○	○	○	○	○	○	○
Sitios web de noticias	○	○	○	○	○	○	○

En su opinión, ¿qué tan serio es el tema del COVID-19 en ${e://Field/country}?

- Nada serio
- Poco serio
- Algo serio
- Muy serio
- No sé

Pensando en COVID-19, ¿qué tema le preocupa más?

- ○ No poder educar a los jóvenes
- ○ Salud mental
- ○ Impacto económico
- ○ Salud física
- ○ Impacto político
- ○ No estoy preocupado por el COVID-19
- ○ No sé

Para que el COVID-19 pare de propagarse, ¿qué porcentaje de personas piensa que necesita vacunarse?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Hasta qué punto está usted de acuerdo o en desacuerdo con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
Confío en que expertos médicos internacionales desarrollen vacunas seguras y eficaces.	○	○	○	○	○
Vacunarme es una buena manera para protegerme de enfermedades.	○	○	○	○	○
Confío que el gobierno determine si las vacunas son seguras y eficaces.	○	○	○	○	○
Vacunarme contra enfermedades que pueden ser graves es importante para la salud de los demás en mi comunidad.	○	○	○	○	○
Generalmente, sigo las indicaciones de mi médico sobre vacunaciones.	○	○	○	○	○

¿Alguna vez ha rechazado una vacuna recomendada para usted o sus hijos?

- ○ No
- ○ Sí
- ○ No sé
- ○ Prefiero no decir
- ○ No aplica

¿Cuáles de las siguentes opciones describe por qué duda en tomar una vacuna en contra del COVID-19? Seleccione todas las que correspondan.

- [ ] Ya tuve COVID-19
- [ ] Temo que las vacunas están siendo desarolladas demasiado rápido
- [ ] Mi riesgo de contraer el COVID-19 es tan bajo que no necesito la vacuna
- [ ] Estoy preocupado por los efectos secundarios
- [ ] No creo que las vacunas sean efectivas contra el COVID-19
- [ ] No confió en el gobierno
- [ ] Temo que la vacuna me dará COVID-19
- [ ] Prefiero adquirir inmunidad tras contraer COVID-19, sin necesidad de una vacuna
- [ ] Temo que no podré pagar una vacuna para el COVID-19
- [ ] Estoy en contra de las vacunas
- [ ] _____ Otra:

¿Sufre de algunas de las siguientes enfermedades crónicas? Seleccione todas las que correspondan.

- [ ] Ninguna
- [ ] Enfermedades cardiovasculares
- [ ] Enfermedades autoinmunes
- [ ] Diabetes
- [ ] Enfermedad pulmonar obstructiva crónica
- [ ] Obesidad
- [ ] Prefiero no decir

¿Ha sido diagnosticado con COVID-19?

- ○ No, nunca he sido diagnosticado con COVID-19
- ○ Sí, actualmente tengo COVID-19
- ○ Sí, he tenido COVID-19 en el pasado
- ○ Prefiero no decir

¿Conoce a alguien que se enfermó gravemente o falleció debido a COVID-19?

- ○ No
- ○ Sí
- ○ No sé

¿Considera usted que su situación económica personal es peor, igual, o mejor que antes de la pandemia?

- ○ Mucho peor
- ○ Peor
- ○ Igual
- ○ Mejor
- ○ Mucho mejor
- ○ No sé

En su opinión, ¿cuán prioritario es para el gobierno distribuir una vacuna en su municipio?

- ○ No es una prioridad
- ○ Una prioridad baja
- ○ Una prioridad media
- ○ Una prioridad alta
- ○ Una máxima prioridad
- ○ No sé

Hoy en día cuando se habla de **tendencias políticas**, mucha gente habla de aquellos que simpatizan más con la izquierda o con la derecha. Según el sentido que tengan para usted los términos "izquierda" y "derecha" cuando piensa sobre su punto de vista político, ¿dónde se encontraría usted en esta escala?

0 (extrema izquierda)	1	2	3	4	5 (centro)	6	7	8	9	10 (extrema derecha)
○	○	○	○	○	○	○	○	○	○	○

Con respecto al manejo de la pandemia, ¿qué tan satisfecho está usted con las siguientes autoridades?

	Nada satisfecho	No satisfecho	Ni satisfecho ni insatisfecho	Satisfecho	Muy satisfecho
Presidente ${e://Field/president}	○	○	○	○	○
${e://Field/health_ministry}	○	○	○	○	○
${e://Field/mayor_gender} de su municipalidad	○	○	○	○	○

Si hubiese una **elección presidencial** mañana, ¿votaría usted a favor del partido o alguien de la coalición del Presidente ${e://Field/president}?

- ○ No, votaría por un candidato de la oposición
- ○ Sí
- ○ No votaría
- ○ No sé

¿Por cuál partido de la oposición votaría en una elección presidencial?

- PAN
- PRI
- PRD
- PT
- PVEM
- MC
- PES
- RSP
- FSP
- [ ] Otro:
- No sé

Si la **elección para ${e://Field/mayor} en su municipio** fuese mañana, ¿votaría usted a favor del partido o alguien de la coalición del actual ${e://Field/mayor}?

- » Sí
- » No, votaría por un candidato de la oposición
- » No votaría
- » No sé

¿Por cuál partido de la oposición votaría en las elecciones locales (o en la elección para ${e://Field/mayor})?

- » PAN
- » PRI
- » PRD
- » PT
- » PVEM
- » MC
- » PES
- » RSP
- » FSP
- [ ] » Otro:
- » No sé

¿Cuánta confianza tiene en las siguientes personas e instituciones?

	Nada de confianza	Poca confianza	Algo de confianza	Mucha confianza	No sé
Presidente ${e://Field /president}	○	○	○	○	○
${e://Field /mayor_gender_2} de mi municipio	○	○	○	○	○
${e://Field /health_ministry}	○	○	○	○	○
${e://Field /medical_association}	○	○	○	○	○
${e://Field /left_newspaper}	○	○	○	○	○
${e://Field /right_newspaper}	○	○	○	○	○
${e://Field /religious_leader}	○	○	○	○	○

¿Cuánta confianza tiene en las siguientes instituciones y organizaciones?

	Nada de confianza	Poca confianza	Algo de confianza	Mucha confianza	No sé
Sus profesionales locales de salud	○	○	○	○	○
Organizaciones de la sociedad civil	○	○	○	○	○
Las fuerzas armadas de ${e://Field/country}	○	○	○	○	○

¿Cuánta confianza tiene en los gobiernos actuales de los siguientes países?

	Nada de confianza	Poca confianza	Algo de confianza	Mucha confianza	No sé
China	○	○	○	○	○
Estados Unidos bajo Donald Trump	○	○	○	○	○
Estados Unidos bajo Joe Biden	○	○	○	○	○
Reino Unido	○	○	○	○	○
Rusia	○	○	○	○	○

¿Hasta qué punto cree usted que reunirse con personas fuera de su familia, en lugares cerrados, contribuye a propagar el COVID-19?

- ○ Nada
- ○ Un poco
- ○ Algo
- ○ Mucho
- ○ No sé

Haga de cuenta que usted tiene la posibilidad de lanzar una moneda justa. Si la moneda cae en cara, obtendrá ${e://Field/risk_currency}. Si no, obtendrá 0 ${e://Field/currency}. Eso significa que tiene una probabilidad del 50% de obtener los ${e://Field/risk_currency} y una probabilidad del 50% de obtener nada. **¿Qué prefiere: tomar el riesgo, o recibir una cantidad segura?** Seleccione una respuesta para cada una de las opciones.

	Tomar el riesgo	Tomar el dinero seguro
Tomar el riesgo de recibir ${e://Field/risk_currency} con una probabilidad del 50% **o recibir ${e://Field/sure_1_currency} asegurados**	○	○
Tomar el riesgo de recibir ${e://Field/risk_currency} con una probabilidad del 50% **o ${e://Field/sure_2_currency} asegurados**	○	○
Tomar el riesgo de recibir ${e://Field/risk_currency} con una probabilidad del 50% **o ${e://Field/sure_3_currency} asegurados**	○	○
Tomar el riesgo de recibir ${e://Field/risk_currency} con una probabilidad del 50% **o ${e://Field/sure_4_currency} asegurados**	○	○
Tomar el riesgo de recibir ${e://Field/risk_currency} con una probabilidad del 50% **o ${e://Field/sure_5_currency} asegurados**	○	○

Haga de cuenta que usted tiene la posibilidad de obtener ${e://Field/sure_1_currency} en este momento, o una cantidad superior dentro de un año. **¿Qué prefiere recibir: los ${e://Field/sure_1_currency} en este momento o la cantidad superior en un año?** Seleccione una respuesta para cada una de las opciones.

	De Acuerdo	En Desacuerdo
Prefiero ${e://Field/sure_1_currency} en este momento a ${e://Field/discount_1_currency} dentro de un año	○	○
Prefiero ${e://Field/sure_1_currency} en este momento a ${e://Field/discount_2_currency} dentro de un año	○	○
Prefiero ${e://Field/sure_1_currency} en este momento a ${e://Field/discount_3_currency} dentro de un año	○	○
Prefiero ${e://Field/sure_1_currency} en este momento a ${e://Field/discount_4_currency} dentro de un año	○	○

Suponga que a usted le dan ${e://Field/sure_1_currency} y tiene que decidir cuanta

plata donar a una familia con necesidad en su comunidad. ¿Cuánto de esos ${e://Field/sure_1_currency} donaría a esta familia?

¿Qué tan importante para usted es recibir el respeto y el reconocimiento de otros en su comunidad?

- Nada importante
- Poco importante
- Algo importante
- Muy importante

¿Cuánta influencia cree usted que tiene con otras personas de su comunidad?

- Nada de influencia
- Poca influencia
- Algo de influencia
- Mucha influencia

Information treatment T0 - Control

Los países de Latinoamérica están comenzando a distribuir sus primeras dosis de vacunas.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T1 - Health only

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demonstrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T2 - Health and herd 60%

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagararse.

Algunos expertos dicen que **al menos 60% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

¿Es cierto que algunos expertos dicen que al menos 60% de las personas necesitarán vacunarse para evitar la propagación del COVID-19?

- ○ Es cierto
- ○ Es falso
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T3 - Health and herd 70%

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagararse.

Algunos expertos dicen que **al menos 70% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

¿Es cierto que algunos expertos dicen que al menos 70% de las personas necesitarán vacunarse para evitar la propagación del COVID-19?

- ○ Es cierto
- ○ Es falso
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T4 - Health and herd 80%

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagararse.

Algunos expertos dicen que **al menos 80% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

¿Es cierto que algunos expertos dicen que al menos 80% de las personas necesitarán vacunarse para evitar la propagación del COVID-19?

- ○ Es cierto
- ○ Es falso
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T5 - Health and herd 60% and current level

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente eficaces** en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagarse.

Algunos expertos dicen que **al menos 60% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

Datos recientes indican que **${e://Field/current_willingness} de las personas en ${e://Field/country} actualmente dicen que se vacunarían** contra el COVID-19.

En ${e://Field/country}, ¿están más o menos personas dispuestas a tomar una vacuna que el 60% de las personas que algunos expertos dicen que necesitarán tomar la vacuna para evitar la propagación del COVID-19?

- ○ **Más del 60%** están dispuestos a tomar una vacuna
- ○ **Menos del 60%** están dispuestos a tomar una vacuna
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T6 - Health and herd 70% and current level

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente**

eficaces en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagarse.

Algunos expertos dicen que **al menos 70% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

Datos recientes indican que **${e://Field/current_willingness} de las personas en ${e://Field/country} actualmente dicen que se vacunarían** contra el COVID-19.

En ${e://Field/country}, ¿están más o menos personas dispuestas a tomar una vacuna que el 70% de las personas que algunos expertos dicen que necesitarán tomar la vacuna para evitar la propagación del COVID-19?

- ○ **Más del 70%** están dispuestos a tomar una vacuna
- ○ **Menos del 70%** están dispuestos a tomar una vacuna
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T7 - Health and herd 80% and current level

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente**

eficaces en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ningún país ha aprobado el uso de vacunas contra el COVID-19
- [ ] No es posible contraer COVID-19 de una vacuna
- [ ] Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- [ ] No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- [ ] Las vacunas se han sometido a exhaustivas pruebas clínicas
- [ ] Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si suficientes personas se vacunan contra el COVID-19, el Coronavirus dejará de propagarse.

Algunos expertos dicen que **al menos 80% de las personas necesitan vacunarse para evitar la propagación del Coronavirus**.

Datos recientes indican que **${e://Field/current_willingness} de las personas en ${e://Field/country} actualmente dicen que se vacunarían** contra el COVID-19.

En ${e://Field/country}, ¿están más o menos personas dispuestas a tomar una vacuna que el 80% de las personas que algunos expertos dicen que necesitarán tomar la vacuna para evitar la propagación del COVID-19?

- ○ **Menos del 80%** están dispuestos a tomar una vacuna
- ○ **Más del 80%** están dispuestos a tomar una vacuna
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Information treatment T8 - Health and Biden vaccinated

Los países de Latinoamerica están comenzando a distribuir sus primeras dosis de vacunas.

La siguiente pantalla proporcionará **información importante sobre estas vacunas** contra el COVID-19.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Las vacunas están diseñadas para **prevenir enfermedades**.

Después de **pruebas exhaustivas realizadas por expertos médicos**, se ha aprobado el uso de varias vacunas contra el COVID-19 en diferentes países.

Las pruebas clínicas han demostrado que las vacunas son **seguras y altamente**

eficaces en prevenir infecciones leves y graves de COVID-19. Los **efectos secundarios son generalmente menores** y no se puede contraer COVID-19 de una vacuna.

¿Cuáles de las siguientes afirmaciones son **ciertas** sobre las vacunas nuevas contra el COVID-19? Seleccione todas las que correspondan.

- ☐ Las vacunas se han sometido a exhaustivas pruebas clínicas
- ☐ No es posible contraer COVID-19 de una vacuna
- ☐ Ningún país ha aprobado el uso de vacunas contra el COVID-19
- ☐ Las pruebas muestran que las vacunas son altamente eficaces en prevenir infecciones de COVID-19
- ☐ No se sabe si hay efectos secundarios graves de tomar una vacuna contra el COVID-19
- ☐ Ninguno de los anteriores

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Hace algunas semanas, **el presidente Joe Biden recibió, de manera segura, una vacuna** contra el COVID-19 en los Estados Unidos.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

No motivation control M0

¿Se ha aprobado el uso de una vacuna contra el COVID-19 en algún país?

- ○ Sí
- ○ No
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Economic motivation M1

Cuanto más rápido ${e://Field/country} pueda detener la propagación de COVID-19, más rápido las personas volverán a trabajar.

Si usted se vacuna contra el COVID-19, **ayudará a que la economía se recupere**.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Se ha aprobado el uso de una vacuna contra el COVID-19 en algún país?

- ○ Sí
- ○ No
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Social incentive motivation M2

Vacunarse contra el COVID-19 demuestra que usted se preocupa por los demás en su comunidad.

Si usted se vacuna contra el COVID-19, **será respetado por las personas en su comunidad**.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Se ha aprobado el uso de una vacuna contra el COVID-19 en algún país?

- ○ No
- ○ Sí
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Altruism motivation M3

Vacunarse contra el COVID-19 ayuda a detener la propagación del COVID-19 y así evita que los más vulnerables se enfermen.

Si usted se vacuna contra el COVID-19, **ayudará a mantener saludables a otros en su comunidad**.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Se ha aprobado el uso de una vacuna contra el COVID-19 en algún país?

- ○ No
- ○ Sí
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Treatment comprehension

En las pruebas clínicas de las vacunas contra el COVID-19, ¿qué tipo de efectos secundarios han tenido los participantes generalmente?

- ○ No han tenido efectos secundarios
- ○ Efectos secundarios menores
- ○ Efectos secundarios graves
- ○ No sé

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Ahora nos gustaría reevaluar sus puntos de vista sobre tomar una vacuna contra el COVID-19.

Response to treatment

En base a la información que acaba de recibir, ¿se han contestado algunas de las dudas que tenía sobre las vacunas contra el COVID-19? Seleccione todas las que correspondan.

- [ ] Ya no pienso que mi riesgo de contraer el COVID-19 es tan bajo que no necesito la vacuna
- [ ] Aunque ya tuve COVID-19, ahora prefiero tomar una vacuna contra el COVID-19
- [ ] Ya no me preocupan los efectos secundarios
- [ ] Ya no prefiero adquirir inmunidad tras contraer COVID-19, sin necesidad de una vacuna
- [ ] Ahora confío en el gobierno
- [ ] Ya no temo que las vacunas se están siendo desarolladas demasiado rápido
- [ ] Ya no temo que la vacuna me dará COVID-19
- [ ] Ahora pienso que las vacunas son efectivas contra el COVID-19
- [ ] Ya no temo que no podré pagar una vacuna para el COVID-19
- [ ] [ ] Otra:

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Post-treatment questions

¿Hasta qué punto está usted de acuerdo o en desacuerdo?

Si una vacuna contra el COVID-19 estuviera disponible, yo me vacunaría.

- ○ Muy en desacuerdo
- ○ En desacuerdo
- ○ Ni de acuerdo ni en desacuerdo
- ○ De acuerdo
- ○ Muy de acuerdo
- ○ No estoy seguro

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para usted ahora, ¿cuántos meses esperaría antes de vacunarse?

- ○ [ ] Numero de meses:
- ○ Nunca tomaría una vacuna

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para todos ahora, aproximadamente ¿qué porcentaje de personas de su municipio piensa que se vacunarían?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Si una vacuna contra el COVID-19 estuviera disponible para todos ahora, aproximadamente ¿qué porcentaje de personas de su municipio piensa que se vacunarían **durante los primeros dos meses de su disponibilidad**?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Qué tan probable es que motive a familiares o amigos a que se vacunen?

- Nada probable
- Poco probable
- Algo probable
- Muy probable

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Para que el COVID-19 pare de propagarse, ¿qué porcentaje de personas piensa que necesitan vacunarse?

0 25 50 75 100

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

¿Dentro de cuántos meses cree que las cosas regresarán a la normalidad en ${e://Field/country}?

- Número de meses:
- Nunca regresarán a la normalidad

Si recibe la vacuna contra el COVID-19, ¿qué tan probable es que le diga a otros que usted se vacunó?

- Nada probable
- Poco probable
- Algo probable
- Muy probable

¿Qué tan importante es para usted vacunarse para detener la propagación del virus en su comunidad?

- ○ Nada importante
- ○ Poco importante
- ○ Algo importante
- ○ Muy importante

¿Qué tan importante es para usted vacunarse para ayudar a que todos puedan regresar a trabajar normalmente?

- ○ Nada importante
- ○ Poco importante
- ○ Algo importante
- ○ Muy importante

Conjoint experiment 1

A pesar que gente en varios países está empezando a recibir una vacuna contra el COVID-19, no habrá vacunación diponsible para todos hasta dentro de varios meses.

Además, todavía no se sabe qué vacunas estarán disponibles para la mayoría de la población.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Por tanto, nos gustaría saber qué tan probable es que decida vacunarse en base a diferentes escenarios.

Lea atentamente toda la información sobre cada escenario antes de responder a las preguntas sobre ese escenario.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

*Suponga que ${e://Field/country} ha obtenido* ***${e://Field/vaccine_1}${e://Field/efficacy_1}***

Esta vacuna es gratis para todos y ***${e://Field/endorser_1}*** *recomienda que todos se vacunen lo más pronto posible.*

La vacuna será administrada por ***${e://Field/distribution_1} ${e://Field/uptake_1}***

Si esta vacuna estuviese disponible, me vacunaría.

- ○ No
- ○ Sí
- ○ No sé

Si esta vacuna estuviese disponible, ¿cuántos meses esperaría para vacunarse?

- ○ [ ] Número de meses:
- ○ Nunca tomaría esta vacuna

Si esta vacuna estuviese disponible, ¿cuán de acuerdo está con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
La propagación de COVID-19 terminará rapidamente.	○	○	○	○	○
Sería muy poco probable que me dé COVID-19 si recibo esta vacuna.	○	○	○	○	○
Sería muy poco probable que sufra algún daño si recibo esta vacuna.	○	○	○	○	○
Esta campaña de vacunación del gobierno es para ayudar a los ciudadanos.	○	○	○	○	○

These page timer metrics will not be displayed to the recipient.

First Click: *0 seconds*

Last Click: *0 seconds*

Page Submit: *0 seconds*

Click Count: *0 clicks*

Conjoint experiment 2

Ahora, le mostraremos un **escenario diferente**.

*Suponga que ${e://Field/country} ha obtenido **${e://Field/vaccine_2}${e://Field/efficacy_2}***

*Esta vacuna es gratis para todos y **${e://Field/endorser_2}** recomienda que todos se vacunen lo más pronto posible.*

*La vacuna será administrada por **${e://Field/distribution_2} ${e://Field/uptake_2}***

Si esta vacuna estuviese disponible, me vacunaría.

- ○ No
- ○ Sí
- ○ No sé

Si esta vacuna estuviese disponible, ¿cuántos meses esperaría para vacunarse?

- ○ _____ Número de meses:
- ○ Nunca tomaría esta vacuna

Si esta vacuna estuviese disponible, ¿cuán de acuerdo está con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
» La propagación de COVID-19 terminará rapidamente.	○	○	○	○	○
» Sería muy poco probable que me dé COVID-19 si recibo esta vacuna.	○	○	○	○	○
» Sería muy poco probable que sufra algún daño si recibo esta vacuna.	○	○	○	○	○
» Esta campaña de vacunación del gobierno es para ayudar a los ciudadanos.	○	○	○	○	○

These page timer metrics will not be displayed to the recipient.

First Click: *0 seconds*

Last Click: *0 seconds*

Page Submit: *0 seconds*

Click Count: *0 clicks*

Conjoint experiment 3

Ahora, le mostraremos un **escenario diferente**.

*Suponga que ${e://Field/country} ha obtenido **${e://Field/vaccine_3}${e://Field/efficacy_3}***

*Esta vacuna es gratis para todos y **${e://Field/endorser_3}** recomienda que todos se vacunen lo más pronto posible.*

La vacuna será administrada por ***${e://Field/distribution_3} ${e://Field/uptake_3}***

Si esta vacuna estuviese disponible, me vacunaría.

- ○ No
- ○ Sí
- ○ No sé

Si esta vacuna estuviese disponible, ¿cuántos meses esperaría para vacunarse?

- ○ _____ Número de meses:
- ○ Nunca tomaría esta vacuna

Si esta vacuna estuviese disponible, ¿cuán de acuerdo está con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
» La propagación de COVID-19 terminará rapidamente.	○	○	○	○	○
» Sería muy poco probable que me dé COVID-19 si recibo esta vacuna.	○	○	○	○	○
» Sería muy poco probable que sufra algún daño si recibo esta vacuna.	○	○	○	○	○
» Esta campaña de vacunación del gobierno es para ayudar a los ciudadanos.	○	○	○	○	○

These page timer metrics will not be displayed to the recipient.

First Click: *0 seconds*

Last Click: *0 seconds*

Page Submit: *0 seconds*

Click Count: *0 clicks*

Conjoint experiment 4

Ahora, le mostraremos un **escenario diferente**.

*Suponga que ${e://Field/country} ha obtenido **${e://Field/vaccine_4}${e://Field/efficacy_4}***

*Esta vacuna es gratis para todos y **${e://Field/endorser_4}** recomienda que todos se vacunen lo más pronto posible.*

La vacuna será administrada por ***${e://Field/distribution_4} ${e://Field/uptake_4}***

Si esta vacuna estuviese disponible, me vacunaría.

- ○ No
- ○ Sí
- ○ No sé

Si esta vacuna estuviese disponible, ¿cuántos meses esperaría para vacunarse?

- ○ _____ Número de meses:
- ○ Nunca tomaría esta vacuna

Si esta vacuna estuviese disponible, ¿cuán de acuerdo está con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
» La propagación de COVID-19 terminará rapidamente.	○	○	○	○	○
» Sería muy poco probable que me dé COVID-19 si recibo esta vacuna.	○	○	○	○	○
» Sería muy poco probable que sufra algún daño si recibo esta vacuna.	○	○	○	○	○
» Esta campaña de vacunación del gobierno es para ayudar a los ciudadanos.	○	○	○	○	○

These page timer metrics will not be displayed to the recipient.

First Click: *0 seconds*

Last Click: *0 seconds*

Page Submit: *0 seconds*

Click Count: *0 clicks*

Conjoint experiment 5

Ahora, le mostraremos un **escenario diferente**. Este es el último escenario.

*Suponga que ${e://Field/country} ha obtenido **${e://Field/vaccine_5}${e://Field/efficacy_5}***

*Esta vacuna es gratis para todos y **${e://Field/endorser_5}** recomienda que todos se vacunen lo más pronto posible.*

La vacuna será administrada por ***${e://Field/distribution_5} ${e://Field/uptake_5}***

Si esta vacuna estuviese disponible, me vacunaría.

- ○ No
- ○ Sí
- ○ No sé

Si esta vacuna estuviese disponible, ¿cuántos meses esperaría para vacunarse?

- ○ _____ Número de meses:
- ○ Nunca tomaría esta vacuna

Si esta vacuna estuviese disponible, ¿cuán de acuerdo está con las siguientes declaraciones?

	Muy en desacuerdo	En desacuerdo	Ni de acuerdo ni en desacuerdo	De acuerdo	Muy de acuerdo
» La propagación de COVID-19 terminará rapidamente.	○	○	○	○	○
» Sería muy poco probable que me dé COVID-19 si recibo esta vacuna.	○	○	○	○	○
» Sería muy poco probable que sufra algún daño si recibo esta vacuna.	○	○	○	○	○
» Esta campaña de vacunación del gobierno es para ayudar a los ciudadanos.	○	○	○	○	○

These page timer metrics will not be displayed to the recipient.

First Click: *0 seconds*

Last Click: *0 seconds*

Page Submit: *0 seconds*

Click Count: *0 clicks*

Open-ended question and nationality

Pensando en los diferentes escenarios que usted ha visto, ¿qué factores lo harían más dispuesto a tomar una vacuna sobre otra? Por favor, sea breve en su respuesta.

¿Cuál es su nacionalidad?

Behavioral question

¿Quisiera recibir un link de la Organización Panamericana de la Salud con más información sobre las vacunas del COVID-19?

Si usted selecciona sí, lo verá en la siguiente pantalla.

- ○ No
- ○ Sí

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

Este es el enlace: haga click aquí.

Este enlace abrirá en una nueva pestaña; por favor recuerde completar la encuesta.

These page timer metrics will not be displayed to the recipient.
First Click: *0 seconds*
Last Click: *0 seconds*
Page Submit: *0 seconds*
Click Count: *0 clicks*

References

[1] DellaVigna, S, Gentzkow, M. Persuasion: Empirical Evidence. Annual Review of Economics. 2010;2(1):643-699.

[2] Lee DS. Training, wages, and sample selection: Estimating sharp bounds on treatment effects. Review of Economic Studies. 2009;76(3):1071-1102.